<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="hwp">eLife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">06266</article-id><article-id pub-id-type="doi">10.7554/eLife.06266</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Computational and Systems Biology</subject></subj-group></article-categories><title-group><article-title>Dynamics of preventive vs post-diagnostic cancer control using low-impact measures</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-19951"><name><surname>Akhmetzhanov</surname><given-names>Andrei R</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-23540"><name><surname>Hochberg</surname><given-names>Michael E</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-3"/><xref ref-type="other" rid="par-4"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution content-type="dept">Institut des Sciences de l'Evolution de Montpellier</institution>, <institution>University of Montpellier</institution>, <addr-line><named-content content-type="city">Montpellier</named-content></addr-line>, <country>France</country></aff><aff id="aff2"><label>2</label><institution content-type="dept">Theoretical Biology Lab, Department of Biology</institution>, <institution>McMaster University</institution>, <addr-line><named-content content-type="city">Hamilton</named-content></addr-line>, <country>Canada</country></aff><aff id="aff3"><label>3</label><institution>Santa Fe Institute</institution>, <addr-line><named-content content-type="city">Santa Fe</named-content></addr-line>, <country>United States</country></aff><aff id="aff4"><label>4</label><institution>Wissenschaftskolleg zu Berlin</institution>, <addr-line><named-content content-type="city">Berlin</named-content></addr-line>, <country>Germany</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-1046"><name><surname>Bergstrom</surname><given-names>Carl T</given-names></name><role>Reviewing editor</role><aff><institution>University of Washington</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>mhochber@univ-montp2.fr</email></corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>25</day><month>06</month><year>2015</year></pub-date><pub-date pub-type="collection"><year>2015</year></pub-date><volume>4</volume><elocation-id>e06266</elocation-id><history><date date-type="received"><day>27</day><month>12</month><year>2014</year></date><date date-type="accepted"><day>24</day><month>06</month><year>2015</year></date></history><permissions><copyright-statement>© 2015, Akhmetzhanov and Hochberg</copyright-statement><copyright-year>2015</copyright-year><copyright-holder>Akhmetzhanov and Hochberg</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-06266-v2.pdf"/><abstract><object-id pub-id-type="doi">10.7554/eLife.06266.001</object-id><p>Cancer poses danger because of its unregulated growth, development of resistance, and metastatic spread to vital organs. We currently lack quantitative theory for how preventive measures and post-diagnostic interventions are predicted to affect risks of a life threatening cancer. Here we evaluate how continuous measures, such as life style changes and traditional treatments, affect both neoplastic growth and the frequency of resistant clones. We then compare and contrast preventive and post-diagnostic interventions assuming that only a single lesion progresses to invasive carcinoma during the life of an individual, and resection either leaves residual cells or metastases are undetected. Whereas prevention generally results in more positive therapeutic outcomes than post-diagnostic interventions, this advantage is substantially lowered should prevention initially fail to arrest tumour growth. We discuss these results and other important mitigating factors that should be taken into consideration in a comparative understanding of preventive and post-diagnostic interventions.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.06266.001">http://dx.doi.org/10.7554/eLife.06266.001</ext-link></p></abstract><abstract abstract-type="executive-summary"><object-id pub-id-type="doi">10.7554/eLife.06266.002</object-id><title>eLife digest</title><p>About one person in every two will get cancer during their lives. Surgery and chemotherapy have long been mainstays of cancer treatment. Both, however, have substantial downsides. Surgery may leave behind undetected cancer cells that can grow into new tumours. Furthermore, in response to chemotherapy drugs, some cancer cells may emerge that resist further treatment. There is therefore interest in whether preventive strategies—including lifestyle changes and medications—could reduce the likelihood of confronting a life-threatening cancer.</p><p>Now, Akhmetzhanov and Hochberg have developed a mathematical model to help compare the effectiveness of preventive strategies and traditional cancer treatments. The model—which assumes that a person can only develop a single cancer from a single region of pre-cancerous cells—suggests that long-term cancer prevention strategies reduce the risk of a life-threatening cancer by more than traditional treatment that begins after a tumour is discovered. The preventive measures may be less effective in some cases compared to traditional treatments if they initially fail to stop a tumour growing, although on average they still work better than treating the cancer after detection.</p><p>According to Akhmetzhanov and Hochberg's model, surgical removal followed by chemotherapy is less likely to be successful than prevention, and when successful, requires larger impacts on the cancer (and therefore creates more side-effects for the patient) to achieve the same level of control as prevention. The model also suggests that even at very low levels of impact on residual cancer cells, chemotherapies are likely to be counterproductive by boosting the subsequent emergence of treatment-resistant tumours.</p><p>Akhmetzhanov and Hochberg's model predicts how effective preventive measures need to be in terms of slowing the growth of cancer cells to result in given reductions in the future risk of a life-threatening cancer. Future work should test this model by measuring the effects on tumour growth of prevention and of traditional therapies.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.06266.002">http://dx.doi.org/10.7554/eLife.06266.002</ext-link></p></abstract><kwd-group kwd-group-type="author-keywords"><title>Author keywords</title><kwd>cancer prevention</kwd><kwd>evolution</kwd><kwd>mathematical model</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001677</institution-id><institution>Institut national de la santé et de la recherche médicale</institution></institution-wrap></funding-source><award-id>CanEvolve PC201306</award-id><principal-award-recipient><name><surname>Hochberg</surname><given-names>Michael E</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001665</institution-id><institution>Agence Nationale de la Recherche</institution></institution-wrap></funding-source><award-id>EvoCan ANR-13-BSV7-0003-001</award-id><principal-award-recipient><name><surname>Hochberg</surname><given-names>Michael E</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004794</institution-id><institution>Centre National de la Recherche Scientifique</institution></institution-wrap></funding-source><award-id>PICS 05313</award-id><principal-award-recipient><name><surname>Hochberg</surname><given-names>Michael E</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution>Réseau National des Systèmes Complexes</institution></institution-wrap></funding-source><award-id>RNSC 2012</award-id><principal-award-recipient><name><surname>Hochberg</surname><given-names>Michael E</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>elife-xml-version</meta-name><meta-value>2.3</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>A model based on empirical parameter estimates predicts that arresting cancer cell growth by less than 1% per day will produce optimal outcomes in preventing life-threatening cancers, and that such preventive measures are generally more successful than post-diagnostic interventions.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Mathematical models play an important role in describing and analysing the complex process of carcinogenesis. Natural selection for increases in tumour cell population growth can be represented as the net effect of increased cell division rates and/or decreased apoptosis (e.g., <xref ref-type="bibr" rid="bib73">Wodarz and Komarova, 2007</xref>). Relatively rare driver mutations confer such a net growth advantage, whereas numerically dominant passenger mutations with initially neutral or mildly deleterious effects (<xref ref-type="bibr" rid="bib53">Marusyk et al., 2012</xref>; <xref ref-type="bibr" rid="bib12">Bozic et al., 2013</xref>; <xref ref-type="bibr" rid="bib54">McFarland et al., 2013</xref>) can increase in frequency due to genetic hitchhiking or subsequent positive selection. Amongst the many passengers in a growing tumour, some can contribute to chemoresistance, and sufficiently large tumours could contain different clones that, taken as a group, can resist some, if not most, chemotherapies (see <xref ref-type="bibr" rid="bib56">Michor et al., 2005</xref> for resistance to imatinib). Chemotherapeutic remission followed by relapse suggests that these resistant cells are often present at low frequencies prior to therapy, either due to genetic drift or costs associated with resistance. Resistant phenotypes subsequently increase in frequency during radiotherapy or chemotherapy, and through competitive release they may incorporate one or more additional drivers, resulting in accelerated growth compared to the original tumour (for related discussion on pathogens, see <xref ref-type="bibr" rid="bib39">Huijben et al., 2013</xref>).</p><p>Previous mathematical studies have considered alternatives to attempting to minimize or eradicate clinically diagnosed cancers with maximum tolerated doses (MTDs) of chemotherapeutic drugs. This body of work indicates that MTD is particularly prone to select for chemoresistance (e.g., <xref ref-type="bibr" rid="bib23">Foo and Michor, 2009</xref>; <xref ref-type="bibr" rid="bib24">Foo and Michor, 2010</xref>; <xref ref-type="bibr" rid="bib51">Lorz et al., 2013</xref>), and what little empirical work exists supports this basic prediction (<xref ref-type="bibr" rid="bib70">Turke et al., 2010</xref>), but see (<xref ref-type="bibr" rid="bib48">Kouyos et al., 2014</xref>) for other disease systems. Numerous alternatives to the goal of cancer minimization/eradication have been proposed and investigated (e.g., <xref ref-type="bibr" rid="bib52">Maley et al., 2004</xref>; <xref ref-type="bibr" rid="bib45">Komarova and Wodarz, 2005</xref>; <xref ref-type="bibr" rid="bib23">Foo and Michor, 2009</xref>; <xref ref-type="bibr" rid="bib28">Gatenby et al., 2009a</xref>, <xref ref-type="bibr" rid="bib29">2009b</xref>; <xref ref-type="bibr" rid="bib12">Bozic et al., 2013</xref>; <xref ref-type="bibr" rid="bib76">Jansen et al., 2015</xref>). For example, <xref ref-type="bibr" rid="bib45">Komarova and Wodarz (2005)</xref> considered how the use of one or multiple drugs could prevent the emergence or curb the growth of chemoresistance. They showed that the evolutionary rate and associated emergence of a diversity of chemoresistant lineages is a major determinant in the success or failure of multiple drugs vs a single one. Lorz and co-workers (<xref ref-type="bibr" rid="bib51">Lorz et al., 2013</xref>) recently modelled the employment of cytotoxic and cytostatic therapies alone or in combination and showed how combination strategies could be designed to be superior in terms of tumour eradication or managing resistance than either agent used alone. <xref ref-type="bibr" rid="bib23">Foo and Michor (2009)</xref> evaluated how different dosing schedules of a single drug could be used to slow the emergence of resistance given toxicity constraints. One of their main conclusions is that drugs slowing the generation of chemoresistant mutants and subsequent evolution are more likely to be successful than those only increasing cell death rates.</p><p>These and other computational approaches have yet to consider the use of preventive measures to reduce cancer-associated morbidity and mortality whilst limiting resistance. Prevention includes life-style changes and interventions or therapies in the absence of detectable invasive carcinoma (e.g., <xref ref-type="bibr" rid="bib21">Etzioni et al., 2003</xref>; <xref ref-type="bibr" rid="bib50">Lippman and Lee, 2006</xref>; <xref ref-type="bibr" rid="bib72">William et al., 2009</xref>; <xref ref-type="bibr" rid="bib38">Hochberg et al., 2013</xref>), for example, reduced cigarette consumption (<xref ref-type="bibr" rid="bib17">Doll and Peto, 1976</xref>) or chemoprevention (<xref ref-type="bibr" rid="bib67">Steward and Brown, 2013</xref>). In depth consideration of preventive measures and their likely impact on individual risk and epidemiological trends is important given the likelihood that all individuals harbour pre-cancerous lesions, some of which may transform into invasive carcinoma (<xref ref-type="bibr" rid="bib10">Bissell and Hines, 2011</xref>; <xref ref-type="bibr" rid="bib36">Greaves, 2014</xref>), and concerns as to whether technological advances will continue to make significant headway in treating clinically detected cancers (<xref ref-type="bibr" rid="bib35">Gillies et al., 2012</xref>; <xref ref-type="bibr" rid="bib71">Vogelstein et al., 2013</xref>).</p><p>Here, we model how continuous, constant measures affect tumour progression and the emergence of resistant lineages. We assume that an individual can contract at most a single cancer, originating from a single lesion. Importantly, we consider cases where the measure may select for the evolution of resistant phenotypes and cases where no resistance is possible. Our approach is to quantify the daily extent to which a growing neoplasm must be arrested in order to either eradicate it or to delay a potentially lethal cancer. Several authors have previously argued how constant or intermittent low toxicity therapies either before or after tumour discovery could be an alternative to MTD chemotherapies (<xref ref-type="bibr" rid="bib74">Wu and Lippman, 2011</xref>; <xref ref-type="bibr" rid="bib38">Hochberg et al., 2013</xref>), but to our knowledge, no study has actually quantified based on empirical parameter estimates, the extent to which cancer cell population growth needs to be arrested for such approaches to succeed (see related discussion in <xref ref-type="bibr" rid="bib11">Bozic et al., 2010</xref>; <xref ref-type="bibr" rid="bib33">Gerstung et al., 2011</xref>; <xref ref-type="bibr" rid="bib12">Bozic et al., 2013</xref>). Below we employ the terms ‘treatment’, ‘measure’, and ‘therapy’ interchangeably, all indicating intentional measures to arrest cancer cell population growth.</p><p>We first derive analytical expressions for the expected total number of cells within a tumour at any given time. We explore dynamics of tumour sizes at given times, and times to detection for given tumour sizes. Specifically, we show that the expected mean tumour size in a population of subjects can be substantially different from the median, since the former is highly influenced by outliers due to tumours of very large size. We then consider constant preventive measures and show that treatment outcome is sensitive to initial conditions, particularly for intermediate-sized tumours. Importantly, we provide approximate conditions for tumour control both analytically and numerically using empirical parameter estimates. We next consider post-diagnostic interventions in which tumour resection either is not complete and leaves residual cells or undetected metastases are present. We contrast these with prevention scenarios where (1) there is no difference in the age at which either prevention or post-diagnostic intervention commences, and (2) prevention and post-diagnostic interventions are alternatives, that is, the former always occurs before the latter. We show as expected that therapeutic outcomes are generally superior under prevention vs post-diagnostic intervention, and that higher impacts on the cancer cell population are usually required for post-diagnostic interventions to achieve a level of control comparable to prevention. Moreover, we find that should resection leave sufficiently large numbers of residual cells (or metastases are not discovered), then a range of the most successful outcomes under prevention is not attainable under post-diagnostic intervention, regardless of potential cell arrest. Finally and importantly, whereas there is little gained in terms of outcomes in post-diagnostic intervention beyond approximately 0.3% cell arrest per day for both small (10,000) and large (1 million) cancer cell populations, prevention outcomes may achieve continual gains for the latter cell number, up to about 0.6% cell arrest per day.</p></sec><sec id="s2"><title>Modeling framework</title><p>Previous study has evaluated the effects of deterministic and stochastic processes on tumour growth and the acquisition of chemoresistance (<xref ref-type="bibr" rid="bib45">Komarova and Wodarz, 2005</xref>; <xref ref-type="bibr" rid="bib11">Bozic et al., 2010</xref>; <xref ref-type="bibr" rid="bib61">Reiter et al., 2013</xref>, see review <xref ref-type="bibr" rid="bib8">Beerenwinkel et al., 2015</xref>). We first consider both processes through exact solutions and numerical simulations of master equations, using the mean field approach (see <xref ref-type="app" rid="app1">Appendix 1</xref> for details). A mean field approach assumes a large initial number of cells (<xref ref-type="bibr" rid="bib49">Krapivsky et al., 2010</xref>) and averages any effects of stochasticity, so that an intermediate state of the system is described by a set of ordinary differential equations (i.e<italic>.</italic>, master equations; <xref ref-type="bibr" rid="bib27">Gardiner, 2004</xref>). Solutions to these are complex even in the absence of the explicit consideration of both drivers and passengers (<xref ref-type="bibr" rid="bib3">Antal and Krapivsky, 2011</xref>; <xref ref-type="bibr" rid="bib43">Kessler and Levine, 2013</xref>).</p><p>We do not explicitly model the different pre-cancerous or invasive carcinoma states. Rather, our approach follows the dynamics of the relative frequencies of subclones, each composed of identical cells (<xref ref-type="bibr" rid="bib6">Baake and Wagner, 2001</xref>; <xref ref-type="bibr" rid="bib63">Saakian and Hu, 2006</xref>). We simulate tumour growth using a discrete time branching process for cell division (<xref ref-type="bibr" rid="bib5">Athreya and Ney, 1972</xref>; <xref ref-type="bibr" rid="bib11">Bozic et al., 2010</xref>). For each numerical experiment, we initiate a tumour of a given size and proportion of resistant cells.</p><p>Briefly, the model framework is as follows. Each cell in a population is described by two characteristics. The first is its resistance status to the measure, which is either ‘not resistant’ (<italic>j</italic> = 0) or ‘resistant’ (<italic>j</italic> = 1). The second property is the number of accumulated driver mutations (maximum <italic>N</italic>) in a given cell line. At each time step of 4 days, cells either divide or die, and when a cell divides, its daughter cell has a probability <inline-formula><mml:math id="inf1"><mml:mi>u</mml:mi></mml:math></inline-formula> of producing a driver mutation and <italic>v</italic> of producing a resistant mutation. We assume no back mutation, and that cells do not compete for space or limiting resources.</p><p>The fitness function <italic>f</italic><sub><italic>ij</italic></sub>, the difference between the birth and death rates of a cell, is defined by the number of accumulated drivers (<italic>i</italic> = 0, 1, …, <italic>N</italic>) and resistance status (<italic>j</italic> = 0, 1): a sensitive cancerous cell with a single driver has selective advantage <italic>s</italic>, and any accumulated driver adds <italic>s</italic> to fitness, while resistance is associated with a constant cost <italic>c</italic>. Exposure to a single treatment affects only non-resistant cells (<italic>j</italic> = 0), incurring a loss <italic>σ</italic> to their fitness. Thus, the fitness function is:<disp-formula id="equ1"><mml:math id="m1"><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi>s</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>−</mml:mo><mml:mi>σ</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>j</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>−</mml:mo><mml:mi>c</mml:mi><mml:mi>j</mml:mi><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula></p><p>The assumption of driver additivity is a special case of multiplicative fitness, and both are approximately equivalent for very small <italic>s</italic>.</p><p>We conducted numerical experiments, each with the same initial states but each using a unique set of randomly generated numbers of a branching process. For each simulation and each time step, the number of cells at time (<italic>t</italic> + 1) was sampled from a multinomial distribution of cells at time <italic>t</italic> (see <xref ref-type="bibr" rid="bib11">Bozic et al., 2010</xref> for details). <xref ref-type="table" rid="tbl1">Table 1</xref> presents baseline parameter values employed in this study. Hereafter, we refer to <italic>σ</italic> as the treatment intensity (applied once every cell cycle of 4 days), while the corresponding daily arrest level to non-resistant cells is approximated by <italic>σ</italic>/4.<table-wrap id="tbl1" position="float"><object-id pub-id-type="doi">10.7554/eLife.06266.024</object-id><label>Table 1.</label><caption><p>Baseline parameter values used in this study</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.06266.024">http://dx.doi.org/10.7554/eLife.06266.024</ext-link></p></caption><table frame="hsides" rules="groups"><thead><tr><th>Parameter</th><th>Variable</th><th>Value</th><th>Range</th><th>Ref.</th></tr></thead><tbody><tr><td>Time step (cell cycle length)</td><td><italic>T</italic></td><td>4 days</td><td>3–4 days</td><td>(<xref ref-type="bibr" rid="bib11">Bozic et al., 2010</xref>)</td></tr><tr><td>Selective advantage</td><td><italic>s</italic></td><td>0.4%</td><td>0.1–1.0%</td><td>(<xref ref-type="bibr" rid="bib11">Bozic et al., 2010</xref>)</td></tr><tr><td>Cost of resistance</td><td><italic>c</italic></td><td>0.1%</td><td/><td/></tr><tr><td>Mutation rate to acquire an additional driver</td><td><italic>u</italic></td><td>3.4 × 10<sup>−5</sup></td><td>10<sup>−7</sup>–10<sup>−2</sup></td><td>(<xref ref-type="bibr" rid="bib11">Bozic et al., 2010</xref>)</td></tr><tr><td>Mutation rate to acquire resistance</td><td><italic>v</italic></td><td>10<sup>−6</sup></td><td>10<sup>−7</sup>–10<sup>−2</sup></td><td>(<xref ref-type="bibr" rid="bib45">Komarova and Wodarz, 2005</xref>)</td></tr><tr><td>Maximal number of additional drivers</td><td><italic>N</italic></td><td>5 (<xref ref-type="fig" rid="fig1 fig2">Figures 1, 2</xref>) 9 (other figures)</td><td>0–9</td><td/></tr><tr><td>Initial cell population</td><td><italic>M</italic><sub>0</sub></td><td>10<sup>6</sup> cells</td><td>–</td><td/></tr><tr><td>Pre-resistance level</td><td><italic>κ</italic></td><td>0.01%</td><td>–</td><td>(<xref ref-type="bibr" rid="bib42">Iwasa et al., 2006</xref>)</td></tr><tr><td>Number of replicate numerical simulations (excluding extinctions)</td><td>–</td><td>10<sup>6</sup></td><td>–</td><td/></tr><tr><td>Detection threshold</td><td><italic>M</italic></td><td>10<sup>9</sup> cells</td><td>10<sup>7</sup>–10<sup>11</sup></td><td>(<xref ref-type="bibr" rid="bib7">Beckman et al., 2012</xref>)</td></tr></tbody></table><table-wrap-foot><fn><p>‘Range’ is values from previous study and employed in the present study.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="s3" sec-type="results"><title>Results</title><sec id="s3-1"><title>Preventive measures</title><p>We first study preventive interventions where a patient has a high risk of developing a cancer and/or a biomarker that indicates the probable presence of a cancer. In either case, so that we can compare and contrast different intervention levels, we assume that the (undetected) tumour contains <italic>M</italic><sub>0</sub> cells when prevention commences. We examine effects on the mean by considering the distribution of tumour sizes at different times using mean-field dynamics (see <xref ref-type="app" rid="app1">Appendix 1</xref>). Numerical experiments were then conducted by assuming that tumours initially contained <italic>M</italic><sub>0</sub> = 10<sup>6</sup> identical cells (<italic>i</italic> = 0), of which 0.01% were resistant. These assumptions are obviously oversimplifications, and we relax some of them below and in the next sections.</p><p>There is an excellent correspondence between analytical and numerical results for <italic>σ</italic> varied in range of <italic>s</italic> (<xref ref-type="fig" rid="fig7">Appendix 1—figure 1A</xref>). A more detailed study of the distribution of tumour sizes reveals that the mean diverges considerably from median behaviour in the majority of cases, since the former is strongly influenced by outliers with high-tumour cell numbers (see <xref ref-type="fig" rid="fig7">Appendix 1—figure 1B</xref>).</p><p><xref ref-type="fig" rid="fig1">Figure 1</xref> shows four examples of numerical experiments. An untreated tumour reaches the assumed detection threshold of 10<sup>9</sup> cells by about 18 years on average and because it is not subject to strong negative selection (we assume low <italic>c</italic>), any emerging resistant cell-lines are likely to remain at low frequency (0.03% at the detection time in the example of <xref ref-type="fig" rid="fig1">Figure 1A</xref>). In <xref ref-type="fig" rid="fig1">Figure 1B</xref>, low-treatment intensity delays tumour growth and thus time of detection by approximately 16 years, while an increase in dose tends to result in tumours dominated by resistant cells (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). Despite being unaffected by treatment, resistant cell populations are sometimes observed to go extinct stemming from stochasticity (<xref ref-type="fig" rid="fig1">Figure 1D</xref>), and this tends to occur more at high-treatment levels, because there are fewer sensitive tumour cells to seed new (mutant) resistant cell populations.<fig id="fig1" position="float"><object-id pub-id-type="doi">10.7554/eLife.06266.003</object-id><label>Figure 1.</label><caption><title>Treatments curb or eliminate tumours.</title><p>Examples of single patient tumour growth for (<bold>A</bold>) no treatment. (<bold>B</bold>) <italic>σ</italic> = 0.6%. (<bold>C</bold>) <italic>σ</italic> = 1.0%. (<bold>D</bold>) <italic>σ</italic> = 2.0%. The shaded area shows the change in total tumour size and the hatched area, the resistant part of a tumour. The treatment intensity σ in this and all other figures are represented as cell arrest per day (σ/4). Parameter values as in <xref ref-type="table" rid="tbl1">Table 1</xref>.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.06266.003">http://dx.doi.org/10.7554/eLife.06266.003</ext-link></p></caption><graphic xlink:href="elife-06266-fig1-v2.tif"/></fig></p><p>We next considered how therapies affected the distribution of tumour detection times in cases where the cancer cell population attained a threshold of 10<sup>9</sup> cells. The magnitude of the selective advantage <italic>s</italic> shows that tumour growth is largely driven by its non-resistant part for relatively low-impact treatments <italic>σ</italic> &lt; 2<italic>s</italic> (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). Importantly, the tumour shifts from being mainly non-resistant to resistant at <italic>σ</italic> ≈ 2<italic>s</italic>, which is reflected by the inflection point in the trajectory of the median (indicated by point <italic>B</italic> in <xref ref-type="fig" rid="fig2">Figure 2A,B</xref>). Notice that detection times are also most variable at <italic>σ</italic> ≈ 2<italic>s</italic>. The median changes smoothly at high-treatment levels (<italic>σ</italic> &gt; 2<italic>s</italic>), tending to a horizontal asymptote. This is explained by the fact that the sensitive part is heavily suppressed at high-treatment levels, meaning that the dynamics are strongly influenced by the actual time point at which the first resistance mutation occurs.<fig-group><fig id="fig2" position="float"><object-id pub-id-type="doi">10.7554/eLife.06266.004</object-id><label>Figure 2.</label><caption><title>Treatment level affects both detection time and frequency of resistance.</title><p>The median (lines) and 90% confidence intervals (shaded areas) of detection times, measured as years beyond the initiation of the preventive measure. Effects of: (<bold>A</bold>) the selective advantage of each additional driver and (<bold>B</bold>) the cost of resistance. (<bold>C</bold>) Samples of the distribution of detection times (in relative frequencies, adjusted for 3-month bins) for corresponding points, indicated in <bold>A</bold> and <bold>B</bold>. Dashed black line is the mean and the dashed-and-dotted line is the median. The colour-code indicates the average level of resistance in detected tumours over 3 month intervals (see inset in <bold>B</bold>). All cells <italic>j</italic> = 0 at <italic>t</italic> = 0. Other parameters as in <xref ref-type="table" rid="tbl1">Table 1</xref>. Detection time is log-transformed in <bold>A</bold> and <bold>B</bold>.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.06266.004">http://dx.doi.org/10.7554/eLife.06266.004</ext-link></p></caption><graphic xlink:href="elife-06266-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.06266.005</object-id><label>Figure 2—figure supplement 1.</label><caption><title>Sensitivity analysis for several key parameters.</title><p>(<bold>A</bold>) Maximal number of additionally accumulated drivers. (<bold>B</bold>) Initial cell number. (<bold>C</bold>) Level of initial partial resistance of a tumour. (<bold>D</bold>) Presence or absence of resistant cell-lines. Point colour-codes indicate the average level of resistance in detected tumours over 3 month intervals (see inset in <bold>B</bold>). For simplicity, only the median is indicated in <bold>B</bold> and <bold>C</bold> for the baseline case (blue line). Lines and shading otherwise as in <xref ref-type="fig" rid="fig2">Figure 2</xref>. Unless otherwise stated, parameter values as in <xref ref-type="table" rid="tbl1">Table 1</xref>.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.06266.005">http://dx.doi.org/10.7554/eLife.06266.005</ext-link></p></caption><graphic xlink:href="elife-06266-fig2-figsupp1-v2.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.06266.006</object-id><label>Figure 2—figure supplement 2.</label><caption><title>Effects of initial neoplasm size (<bold>A</bold>, <bold>B</bold>) and resistance level (<bold>C</bold>) on preventive measure success.</title><p>Success is defined as tumour non-detection by 50 years. Daily effect of treatment on cellular arrest is assumed to be 0.25%. Unless otherwise stated, parameter values as in <xref ref-type="table" rid="tbl1">Table 1</xref>.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.06266.006">http://dx.doi.org/10.7554/eLife.06266.006</ext-link></p></caption><graphic xlink:href="elife-06266-fig2-figsupp2-v2.tif"/></fig></fig-group></p><p>We find, counterintuitively, that early-detected tumours are more likely to be resistant under constant treatments than those detected at later times (<italic>A, B, and C</italic> in <xref ref-type="fig" rid="fig2">Figure 2C</xref>). This is because tumours under treatment that by chance obtain resistance early grow faster than those that do not. By the time of detection, non-resistant tumours usually accumulate up to 4 additional drivers on average, while resistant tumours have fewer. For larger values of cost <italic>c</italic>, an additional non-regularity emerges at σ ≈ 3s (segment <italic>DEF</italic> in <xref ref-type="fig" rid="fig2">Figure 2B</xref>), and is associated with tumours having a majority of cells with maximum numbers of drivers. This region is also characterized by a different transition to complete resistance (<italic>cf</italic>. <xref ref-type="other" rid="media1">Videos 1</xref>, <xref ref-type="other" rid="media2">2</xref> for relatively low and high costs of resistance, respectively). For example, at point <italic>D</italic>, tumours with a majority of non-resistance have less variable detection times than tumours with a majority of resistant cells (points <italic>E</italic> and <italic>F</italic> in <xref ref-type="fig" rid="fig2">Figure 2B</xref> and corresponding panels in <xref ref-type="fig" rid="fig2">Figure 2C</xref>). Treatment levels along the segment <italic>DEF</italic> result in tumours that are more likely to be resistant as one goes from the centre to the tails of the distribution of detection times. This differs qualitatively from the previous case of a lower cost of resistance, where the tumours are less resistant in the tail of the distribution of detection times (<italic>cf</italic> segments <italic>ABC</italic> and <italic>DEF</italic> in <xref ref-type="fig" rid="fig2">Figure 2B</xref> and corresponding panels in <xref ref-type="fig" rid="fig2">Figure 2C</xref>).<media content-type="glencoe play-in-place height-250 width-310" id="media1" mime-subtype="mp4" mimetype="video" xlink:href="elife-06266-media1.mp4"><object-id pub-id-type="doi">10.7554/eLife.06266.007</object-id><label>Video 1.</label><caption><title>Treatment level affects both detection time and frequency of resistance.</title><p>(<bold>A</bold>) The median (thick line) and 90% confidence intervals (shaded areas with dashed boundaries) for the distribution of detection times. (<bold>B</bold>) Arbitrary samples of the distribution of detection times and distribution of the mean number of accumulated drivers. The colour-code indicates the average level of resistance in detected tumours over 3 month intervals. Parameters as in <xref ref-type="table" rid="tbl1">Table 1</xref>.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.06266.007">http://dx.doi.org/10.7554/eLife.06266.007</ext-link></p></caption></media><media content-type="glencoe play-in-place height-250 width-310" id="media2" mime-subtype="mp4" mimetype="video" xlink:href="elife-06266-media2.mp4"><object-id pub-id-type="doi">10.7554/eLife.06266.008</object-id><label>Video 2.</label><caption><title>Treatment level affects both detection time and frequency of resistance.</title><p>(<bold>A</bold>) The median (thick line) and 90% confidence intervals (shaded areas with dashed boundaries) for the distribution of detection times. (<bold>B</bold>) Arbitrary samples of the distribution of detection times and distribution of the mean number of accumulated drivers. The colour-code indicates the average level of resistance in detected tumours over 3 month intervals. Parameters as in <xref ref-type="table" rid="tbl1">Table 1</xref> except for the cost of resistance <italic>c</italic> = 0.4%.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.06266.008">http://dx.doi.org/10.7554/eLife.06266.008</ext-link></p></caption></media></p><p>The inflection point at <italic>σ</italic> ≈ 2<italic>s</italic> in <xref ref-type="fig" rid="fig2">Figure 2A</xref> is due to the accumulation of additional drivers within tumours and associated increases in the likelihood that the tumour eventually resists treatment. Since the initial population consists of 10<sup>6</sup> cells, in the absence of treatment, a mutant cell with one additional driver and associated fitness 2<italic>s</italic> will appear very rapidly. Such a tumour can be suppressed only if <italic>σ</italic> &gt; 2<italic>s</italic>. This is supported by additional numerical experiments where we vary the maximal number of additional driver mutations <italic>N</italic>: the inflection point <italic>σ</italic> ≈ 2<italic>s</italic> disappears when <italic>N</italic> = 0 (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>). The inflection points at <italic>σ</italic> = 3<italic>s</italic>, 4<italic>s</italic> emerge at treatment levels that effectively suppress sensitive subclones with the most drivers before resistance mutations are obtained (<italic>cf</italic> <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A–C</xref> with <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1D</xref> and <xref ref-type="other" rid="media3">Video 3</xref>). Specifically, the peaked distributions, corresponding to better therapeutic outcomes, tend to disappear when resistant subclones emerge.<media content-type="glencoe play-in-place height-250 width-310" id="media3" mime-subtype="mp4" mimetype="video" xlink:href="elife-06266-media3.mp4"><object-id pub-id-type="doi">10.7554/eLife.06266.009</object-id><label>Video 3.</label><caption><title>Treatment level effects on detection times assuming no resistance is possible.</title><p>(<bold>A</bold>) The median (thick line) and 90% confidence intervals (shaded areas with dashed boundaries) for the distribution of detection times. (<bold>B</bold>) Arbitrary samples of the distribution of detection times and the distribution of the mean number of accumulated drivers. The colour-code indicates the average level of resistance in detected tumours over 3 month intervals. The resistance mutation is knocked out (<italic>v</italic> = 0). Otherwise parameters as in <xref ref-type="table" rid="tbl1">Table 1</xref>.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.06266.009">http://dx.doi.org/10.7554/eLife.06266.009</ext-link></p></caption></media></p><p>The initial cancer cell number <italic>M</italic><sub>0</sub> affects both the median and distribution of detection times (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>). For large initial tumours, growth is deterministic and exponential. As the initial size is decreased from 10<sup>6</sup> to 10<sup>5</sup>, stochastic effects are increasingly manifested by greater variability in tumour inhibition and an inflection point observed at the 95th percentile. Moreover, we find that a tumour is likely to be eradicated under a range of constant treatments when <italic>M</italic><sub>0</sub> = 10<sup>5</sup> or fewer initial cells; in contrast, a tumour is virtually certain to persist regardless of treatment level for <italic>M</italic><sub>0</sub> = 10<sup>7</sup> cells or greater (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2A,B</xref>). In other words, our model indicates that tumours that are <italic>c.</italic> 1% the size of most clinically detectable, internal cancers will typically be impossible to eradicate by single molecule chemoprevention when resistance is possible.</p><p>Given the mutation rates assumed here, many tumours with 1 million cells will either already contain or rapidly subsequently acquire resistant cells (<xref ref-type="bibr" rid="bib42">Iwasa et al., 2006</xref>). It is therefore not surprising that the initial fraction of resistant cells in a tumour has little impact on dynamics (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C</xref>). In contrast, another measure of success in control (the fraction of persons with tumours that remain undetected after 50 years of growth) improves substantially with lower numbers of initial resistance mutations, particularly at higher treatment levels (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2C</xref>). This is because the initial phases of treatment have a major impact on the potential for new resistant mutants: should few be initially present or emerge, they will either go stochastically extinct or will not grow to detection levels (1 billion cells) in the 50 year time frame of these numerical experiments.</p><p>We conducted further sensitivity analyses by varying accumulation rates <italic>u</italic> of additional driver mutations. We find that tumours exhibit more or less deterministic growth depending on the initial number of cells <italic>M</italic><sub>0</sub> and driver mutation rate <italic>u</italic> whereby the larger the population (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>) or the higher the mutation rate (<xref ref-type="fig" rid="fig10">Appendix 1—figure 4A</xref>), the less apparent are stochastic effects. The corresponding analysis is presented in ’Varying mutation rate and initial tumour size‘ in <xref ref-type="app" rid="app1">Appendix 1</xref> and <xref ref-type="fig" rid="fig10">Appendix 1—figure 4</xref>.</p><p>Finally, we considered scenarios where the cost of resistance is dose-dependent and specifically situations of drug addiction (<xref ref-type="bibr" rid="bib16">Das Thakur et al., 2013</xref>). Numerical studies presented in more detail in ’A simple form of drug addiction for resistant cell-lines‘ in <xref ref-type="app" rid="app1">Appendix 1</xref> show that under dose-dependent costs, a drug treatment only applied when the number of non-resistant cells exceeds the number of resistant cells (e.g., a metronomic therapy [<xref ref-type="bibr" rid="bib22">Fischer et al., 2015</xref>]) leads to slower long-term tumour growth than does a constant therapy.</p></sec><sec id="s3-2"><title>Post-diagnostic interventions</title><p>We next investigated how a post-diagnostic measure (usually some form of chemotherapy or radiation therapy, but could also involve adjuvants after an initial therapy) affects the probability of treatment success, the distribution of times for tumour relapse, and resistance levels. We assume that a tumour grows from one cell (<italic>i</italic> = 0, <italic>j</italic> = 0) and is discovered either at 10<sup>9</sup> (early) or 10<sup>11</sup> (very late) cells, whereupon the primary tumour is removed, leaving a small number (10<sup>4</sup> or 10<sup>6</sup>) of residual, and/or undetected or inoperable neighbouring micro-metastatic cells, and/or distant metastatic cells. Below, we contrast this with prevention without discriminating the age at which either intervention type commences, whereas in the following section, we consider these as competing alternatives. <xref ref-type="fig" rid="fig3">Figure 3A</xref> and <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref> present the distributions of driver mutations for each scenario. (Recall that in the previous section, we assumed that when a measure commenced, tumours had no additional drivers (<italic>i</italic> = 0)).<fig-group><fig id="fig3" position="float"><object-id pub-id-type="doi">10.7554/eLife.06266.010</object-id><label>Figure 3.</label><caption><title>Effects of preventive and post-diagnostic interventions against tumours consisting of 1 million cells.</title><p>(<bold>A</bold>) The distribution of mean sizes of subclones (hatched bars = before removal and solid bars = post removal). (<bold>B</bold>) The time distribution of cases in which either intervention type fails to control the tumour below the detection threshold after 50 years (thick line = median, filled area with dashed boundaries = 90% CIs) for different constant treatment intensities. (<bold>C</bold>) The percentage of cases where the tumour consists of less than 100 resistant cells at 4 years after treatment commences (solid lines), and the percentage of cases where tumour size is below the detection threshold 20 years after the measure begins (dashed-and-dotted lines). (<bold>D</bold>) The mean number of accumulated drivers within a tumour at the time of detection. Parameter values as in <xref ref-type="table" rid="tbl1">Table 1</xref>.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.06266.010">http://dx.doi.org/10.7554/eLife.06266.010</ext-link></p></caption><graphic xlink:href="elife-06266-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.06266.011</object-id><label>Figure 3—figure supplement 1.</label><caption><title>Effects of preventive and post-diagnostic interventions against tumours consisting of 10,000 cells.</title><p>Same as <xref ref-type="fig" rid="fig3">Figure 3</xref>, except interventions against 10<sup>4</sup> cancer cells. (<bold>A</bold>) The distribution of mean sizes of subclones for different constant treatment intensities (hatched bars = before removal and solid bars = post removal). (<bold>B</bold>) The time distribution of cases in which either intervention type fails to control the tumour below the detection threshold after 50 years (thick lines = medians, shaded areas with dashed boundaries = 90% CIs). (<bold>C</bold>) The percentage of cases when a tumour consists of less than 100 resistant cells at 4 years post-resection (solid lines) and the percentage of cases when tumour sizes are below the detection threshold 20 years after the measure commences (dashed-and-dotted lines). (<bold>D</bold>) The mean number of accumulated drivers within a tumour at the time of detection. Parameter values as in <xref ref-type="table" rid="tbl1">Table 1</xref>.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.06266.011">http://dx.doi.org/10.7554/eLife.06266.011</ext-link></p></caption><graphic xlink:href="elife-06266-fig3-figsupp1-v2.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.06266.012</object-id><label>Figure 3—figure supplement 2.</label><caption><title>Time to first discovery as a predictor of post-diagnostic treatment success.</title><p>Time to tumour relapse following resection as function of the time it takes for the initial cancer cell to attain 10<sup>9</sup> cells (i.e., the point at which the tumour is discovered, resected, and treatment begins). Each dot represents a numerical simulation from the yellow distribution in <xref ref-type="fig" rid="fig3">Figure 3B</xref> (only 1,000 simulation results out of 10<sup>6</sup>are shown). Four different treatment levels are considered. Black solid line is a simple linear regression, and grey area with dashed boundaries indicates extrapolation of high and low bounds accounting for 95% of observations (prediction interval). The fitted linear regression model gives an intercept of 7.5 years, a slope of 1.6° and <italic>R</italic><sup>2</sup> of 0.024 in (<bold>A</bold>), 10.4 years, 2.2° and <italic>R</italic><sup>2</sup> of 0.017 in (<bold>B</bold>), 12.9 years, 3.0° and <italic>R</italic><sup>2</sup> of 0.009 in (<bold>C</bold>), and 13.1 years, 3.3° and R<sup>2</sup> of 0.008 in (<bold>D</bold>). Parameters as in <xref ref-type="table" rid="tbl1">Table 1</xref>.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.06266.012">http://dx.doi.org/10.7554/eLife.06266.012</ext-link></p></caption><graphic xlink:href="elife-06266-fig3-figsupp2-v2.tif"/></fig><fig id="fig3s3" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.06266.013</object-id><label>Figure 3—figure supplement 3.</label><caption><title>The R2 of regressions from numerical experiments for different treatment levels of time to tumour relapse following resection as function of the mean number of drivers in a resected tumour.</title><p>Time to tumour discovery is generally more predictive of post-diagnostic therapeutic outcome for lower treatment levels. See <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref> for details.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.06266.013">http://dx.doi.org/10.7554/eLife.06266.013</ext-link></p></caption><graphic xlink:href="elife-06266-fig3-figsupp3-v2.tif"/></fig><fig id="fig3s4" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.06266.014</object-id><label>Figure 3—figure supplement 4.</label><caption><title>Mean number of additionally accumulated drivers in resected tumour as a predictor of post-diagnostic treatment success.</title><p>The fitted negative exponential regression model <italic>y</italic> = <italic>a</italic><italic>e</italic><sup>-<italic>bx </italic></sup>gives <italic>a</italic> = 13.5 years, <italic>b</italic> = 0.3 and <italic>R</italic><sup>2</sup> = 0.696 in (<bold>A</bold>), 18.95 years, 0.3 and <italic>R</italic><sup>2</sup> = 0.537 in (<bold>B</bold>), 23.0 years, 0.29 and <italic>R</italic><sup>2</sup> = 0.262 in (<bold>C</bold>), and 23.9 years, 0.3 and <italic>R</italic><sup>2</sup> = 0.224 in (<bold>D</bold>). See <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref> for details.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.06266.014">http://dx.doi.org/10.7554/eLife.06266.014</ext-link></p></caption><graphic xlink:href="elife-06266-fig3-figsupp4-v2.tif"/></fig><fig id="fig3s5" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.06266.015</object-id><label>Figure 3—figure supplement 5.</label><caption><title>The <italic>R</italic><sup>2</sup> of regressions from numerical experiments for different treatment levels of time to tumour relapse following resection as function of the mean number of drivers in a resected tumour.</title><p>Time to tumour discovery is more predictive of post-diagnostic therapeutic outcome for lower treatment levels. See <xref ref-type="fig" rid="fig3s4">Figure 3—figure supplement 4</xref> for details.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.06266.015">http://dx.doi.org/10.7554/eLife.06266.015</ext-link></p></caption><graphic xlink:href="elife-06266-fig3-figsupp5-v2.tif"/></fig></fig-group></p><p>First, we examine the case where post-diagnostic resection leaves 10<sup>6</sup> cells. As suggested by our studies above on prevention, 1 million cells have a high probability of already containing resistant subclones, and deterministic effects dominate subsequent tumour growth dynamics. Comparing the median expectations of years from tumour excision to relapse, early discovery (at 10<sup>9</sup> cells) yields an additional 3.4 years compared to late discovery (at 10<sup>11</sup> cells) at <italic>σ</italic> = 1.5% (medians for low vs high detection thresholds are 14.8 and 11.4 years, respectively; <xref ref-type="fig" rid="fig3">Figure 3B</xref>). Consider the following example: 20 years after resection and commencing treatment, the probability of tumour non-detection (i.e., the tumour is either eradicated or does not reach the detection threshold) is close to zero, regardless of treatment intensity (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). Contrast this with cases of prevention starting at the same cancer cell population size (10<sup>6</sup> cells) but which fail to control the incipient tumour for the 50 years of the simulation: the detection time of these potentially life-threatening tumours is substantially longer than either of the excision cases (median 25.5 years for <italic>σ</italic> = 1.5%, i.e., 0.3–0.4% potential cell arrest per day), and tumours are managed below the detection threshold after 20 years in more than 80% of cases for any <italic>σ</italic> &gt; 1.0% (<xref ref-type="fig" rid="fig3">Figure 3C</xref>).</p><p>Now consider a residual population of 1/100th the previous case, that is, 10<sup>4</sup> cells. Here, stochastic effects play a more important role in dynamics (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A,B</xref>). Due to initial heterogeneity (i.e., the co-occurrence of many subclones), when there are 4 and 5 (5 and 6) additional drivers in the dominant subclones of a residual cancer from an excised tumour of 10<sup>9</sup> (10<sup>11</sup>) cells, we observe a double peak at 4<italic>s</italic> and 5<italic>s</italic> (5<italic>s</italic> and 6<italic>s</italic>) (<italic>cf</italic> <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref>). These peaks in variability of outcomes are a result of the stochastic nature of the appearance of the first resistance mutations and of additional driver mutations. Interestingly, the secondary detection times (i.e., when residual or metastatic cells grow to form a new tumour) are more variable for small initial tumours compared to larger ones (<italic>cf</italic> the median 35.8 years, 90% CIs [17.0, 70.5] years vs 22.4, [13.7, 37.0] years for 10<sup>9</sup> vs 10<sup>11</sup>, respectively, with <italic>σ</italic> = 1.5%). This effect is due to resistance emergence in more aggressive subclones for larger tumours, such that the tumour relapses more deterministically (i.e., with less variability and faster on average). The probability of tumour non-detection after 20 years and the distribution of the mean number of accumulated drivers within tumours are shown in <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1C,D</xref>, respectively (<italic>cf</italic> with the previous case, shown in <xref ref-type="fig" rid="fig3">Figure 3C,D</xref>).</p><p>Importantly, for both thresholds of tumour excision, subsequent cancer cell arrest levels beyond approximately <italic>σ</italic> = 1.5% make little difference in terms of tumour growth (<xref ref-type="fig" rid="fig3">Figure 3B-D</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B-D</xref>), since virtually all of the sensitive cells post-excision will be arrested or killed by the measure beyond this level, leaving uncontrollable resistant cells to grow and repopulate the primary tumour site and/or metastases. (Note that this level is above that found in the previous section. This is because drivers accumulate throughout tumour growth in the results given in <xref ref-type="fig" rid="fig3">Figure 3</xref>, whereas tumours were assumed to only start accumulating the first drivers after growth from <italic>M</italic><sub>0</sub> cells in <xref ref-type="fig" rid="fig2">Figure 2</xref> and <xref ref-type="fig" rid="fig2s1 fig2s2">Figure 2—figure supplements 1, 2</xref>). Moreover, we find that for post-diagnostic interventions knowledge about the number of drivers at the time of tumour discovery is a far better predictor of outcome than information about the time from tumour initiation to discovery, and that increases in treatment intensity tend to decrease predictive accuracy (<xref ref-type="fig" rid="fig3s2 fig3s3 fig3s4 fig3s5">Figure 3—figure supplements 2–5</xref>).</p></sec><sec id="s3-3"><title>Prevention vs post-diagnostic intervention</title><p>The above results consider preventive measures and post-diagnostic interventions as independent rather than alternative approaches. Thus, although prevention delays tumour growth for longer times on average than does post-diagnostic intervention, because prevention is <italic>always</italic> initiated before diagnosis, when considering the relative benefits and risks of each, the actual time gained by the former relative to the latter in terms of cancer-free life will be less than the differences reported in <xref ref-type="fig" rid="fig3">Figure 3B</xref> and <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref>.</p><p><xref ref-type="fig" rid="fig4">Figure 4</xref> presents a hypothetical comparative scenario of prevention vs post-diagnostic intervention. Prevention may either succeed without recurrence, or should the measure initially fail and a tumour be clinically detected, the patient has a ‘second chance’ whereby the tumour is resected and treatment continued (assumed at the same treatment intensity <italic>σ</italic>), either to a further relapse (failure) or non-detection (success) (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). Compare this scenario with the more standard post-diagnostic resection followed by treatment, which either results in relapse or detection-free life (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). These numerical experiments assume the same starting point (time at which the cancer cell population equals <italic>M</italic><sub>0</sub>, and drivers and resistant subclones are present) for each tumour, and because of a ‘second chance’ following initial failure in prevention, are run for a maximum of 50 years after the starting point (same as the numerical studies in the previous section). We also assume, as before, that potential therapeutic resistance mechanisms to all intervention types are identical.<fig id="fig4" position="float"><object-id pub-id-type="doi">10.7554/eLife.06266.016</object-id><label>Figure 4.</label><caption><title>Hypothetical process of preventive (with a ‘second chance’) and post-diagnostic measures.</title><p>A tumour is initiated by one cell and grows to size <italic>M</italic><sub>0</sub> (either 10<sup>4</sup> or 10<sup>6</sup> cells in our numerical studies). Prevention (<bold>A</bold>) arrests tumour growth at intensity <italic>σ</italic> (daily level = <italic>σ</italic>/4). Should the tumour grow to 10<sup>9</sup> cells, it is diagnosed and resected to <italic>M</italic> = <italic>M</italic><sub>0</sub> cells and then treated again at intensity <italic>σ</italic>. Post-diagnostic intervention (<bold>B</bold>) does not discover the growing tumour until 10<sup>9</sup> cells (i.e., <inline-formula><mml:math id="inf2"><mml:mrow><mml:mi>σ</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mover accent="true"><mml:mi>σ</mml:mi><mml:mo>^</mml:mo></mml:mover></mml:mrow><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:math></inline-formula>), whereupon it is resected to <italic>M</italic> = <italic>M</italic><sub>0</sub> cells and then treated at intensity <italic>σ</italic> &gt; 0. Either intervention finally ‘fails’ should the tumour attain 10<sup>9</sup> cells a second time, no later than 50 years after the initial lesion of size <italic>M</italic><sub>0</sub>. Should the tumour be eradicated or not exceed 10<sup>9</sup> cells by 50 years after the initial lesion, then the intervention is deemed a ‘success’.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.06266.016">http://dx.doi.org/10.7554/eLife.06266.016</ext-link></p></caption><graphic xlink:href="elife-06266-fig4-v2.tif"/></fig></p><p><xref ref-type="fig" rid="fig5">Figure 5</xref> presents the comparative outcomes (see also <xref ref-type="other" rid="media4">Videos 4</xref>, <xref ref-type="other" rid="media5">5</xref>). When prevention starts at (or tumour resection misses) relatively large cancer cell populations (1 million cells), only small comparative gains occur from higher cell arrest in terms of outright treatment success (<xref ref-type="fig" rid="fig5">Figure 5A</xref>), whereas interventions starting at much smaller cancer cell numbers (10,000) result in considerably greater outright success (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). Looking at situations of relapse only for prevention vs post-diagnostic intervention, the former generally results in superior outcomes in terms of delaying tumour growth, particularly for large residual cell populations (<italic>cf</italic> <xref ref-type="fig" rid="fig5">Figure 5C,D</xref>). In contrast, for lower numbers of residual cells, some post-diagnostic resected tumours in the sample will be initially resistance free (<italic>cf</italic> <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A,B</xref>). This, together with fewer accumulated drivers in the highest driver subclones, contributes to improved outcomes should relapse occur (<xref ref-type="fig" rid="fig5">Figure 5D</xref>) and overall treatment success at sufficiently high treatment intensities (<xref ref-type="fig" rid="fig5">Figure 5A,B,E,F</xref>). Importantly, resected tumours in both the prevention (when it initially fails) and post-diagnostic scenarios may contain numerous resistant cells (example of 0.25% daily cellular arrest: <xref ref-type="fig" rid="fig5s2 fig5s3">Figure 5—figure supplements 2, 3</xref>). Prior selection for resistance in initially failed prevention generally results in larger residual resistant cell populations than pre-therapeutic residual populations in post-diagnostic situations (filled bars, <italic>cf</italic> captions A and B in <xref ref-type="fig" rid="fig5s2 fig5s3">Figure 5—figure supplements 2, 3</xref>), but smaller residual resistant cell populations than treatment failures following post-diagnostic resection (hatched bars, <italic>cf</italic> captions A and D in <xref ref-type="fig" rid="fig5s2 fig5s3">Figure 5—figure supplements 2, 3</xref>). Note that, as expected, secondary failures are associated with larger percentages of resistant subclones and a shift in the distributions towards more drivers (<italic>cf</italic> captions C and D in <xref ref-type="fig" rid="fig5s2 fig5s3">Figure 5—figure supplements 2, 3</xref>).<fig-group><fig id="fig5" position="float"><object-id pub-id-type="doi">10.7554/eLife.06266.017</object-id><label>Figure 5.</label><caption><title>Comparison of preventive (blue lines and shading) and post-diagnostic (red lines, yellow shading) interventions.</title><p>Tumours are either treated at <italic>M</italic><sub>0</sub> = 10<sup>6</sup> cells (left panels) or <italic>M</italic><sub>0</sub> = 10<sup>4</sup> cells (right panels). (<bold>A</bold>, <bold>B</bold>) Probability of treatment success, defined as the proportion of cases where the tumour remains undetected (either extinct or below 10<sup>9</sup> cells) by 50 years after the initial lesion of <italic>M</italic><sub>0</sub> cells. (<bold>C</bold>, <bold>D</bold>) Distribution of times to relapse for treatment failures. (<bold>E</bold>, <bold>F</bold>) Distribution of detection times for all cases including relapsed tumours and tumours remaining undetected prior to and after 50 years (detection times are assigned to 50 years in the latter case). Parameters as in <xref ref-type="table" rid="tbl1">Table 1</xref>. See <xref ref-type="fig" rid="fig3">Figure 3</xref> for details.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.06266.017">http://dx.doi.org/10.7554/eLife.06266.017</ext-link></p></caption><graphic xlink:href="elife-06266-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.06266.018</object-id><label>Figure 5—figure supplement 1.</label><caption><title>Resistant cell populations after initial failure.</title><p>Tumours are either treated at <italic>M</italic><sub>0</sub> = 10<sup>6</sup>cells (<bold>A</bold>) or <italic>M</italic><sub>0</sub> = 10<sup>4</sup>cells (<bold>B</bold>). Red lines and yellow shading = population following resection. Parameter values as in <xref ref-type="table" rid="tbl1">Table 1</xref>.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.06266.018">http://dx.doi.org/10.7554/eLife.06266.018</ext-link></p></caption><graphic xlink:href="elife-06266-fig5-figsupp1-v2.tif"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.06266.019</object-id><label>Figure 5—figure supplement 2.</label><caption><title>Distribution of mean sizes of subclones.</title><p>(<bold>A</bold>) Cases where a tumour is detected and resected following prevention. (<bold>B</bold>) Cases where a tumour is detected and resected with no prevention. (<bold>C</bold>) Cases of relapse following resection and secondary treatment to initially failed prevention. (<bold>D</bold>) Cases of relapse following resection and primary treatment in cases where there was no prevention. Hatched bars indicate cell numbers in the tumour and solid bar numbers after resection and 10<sup>6</sup> residual or metastatic cells. Daily arresting level assumed to be 0.25%. Parameter values as in <xref ref-type="table" rid="tbl1">Table 1</xref>.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.06266.019">http://dx.doi.org/10.7554/eLife.06266.019</ext-link></p></caption><graphic xlink:href="elife-06266-fig5-figsupp2-v2.tif"/></fig><fig id="fig5s3" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.06266.020</object-id><label>Figure 5—figure supplement 3.</label><caption><title>Distribution of mean sizes of subclones.</title><p>Same as <xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2</xref>, except <italic>M</italic><sub>0</sub> is 10<sup>4</sup> cancer cells.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.06266.020">http://dx.doi.org/10.7554/eLife.06266.020</ext-link></p></caption><graphic xlink:href="elife-06266-fig5-figsupp3-v2.tif"/></fig></fig-group><media content-type="glencoe play-in-place height-250 width-310" id="media4" mime-subtype="mp4" mimetype="video" xlink:href="elife-06266-media4.mp4"><object-id pub-id-type="doi">10.7554/eLife.06266.021</object-id><label>Video 4.</label><caption><title>Comparison of preventive (blue lines and shading) and post-diagnostic (red lines, hatched) interventions.</title><p>Tumours are treated at <italic>M</italic><sub>0</sub> = 10<sup>6</sup> cells. (<bold>A</bold>) The median (thick line) and 90% confidence intervals (shaded areas with dashed boundaries) for the distribution of times to relapse for treatment failures. (<bold>B</bold>) and (<bold>C</bold>) Arbitrary samples of the distribution of detection times for preventive and post-diagnostic interventions, respectively. The colour-code indicates the mean number of accumulated drivers over a period of 1 year. The rectangles on the top of <bold>B</bold> and on the bottom of <bold>C</bold> show the fifth and 95th percentiles, the blue circle indicates the median, and the red line is the mean. Parameters as in <xref ref-type="table" rid="tbl1">Table 1</xref>.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.06266.021">http://dx.doi.org/10.7554/eLife.06266.021</ext-link></p></caption></media><media content-type="glencoe play-in-place height-250 width-310" id="media5" mime-subtype="mp4" mimetype="video" xlink:href="elife-06266-media5.mp4"><object-id pub-id-type="doi">10.7554/eLife.06266.022</object-id><label>Video 5.</label><caption><title>Comparison of preventive (blue lines and shading) and post-diagnostic (red lines, hatched) interventions.</title><p>Tumours are treated at <italic>M</italic><sub>0</sub> = 10<sup>4</sup> cells. (<bold>A</bold>) The median (thick line) and 90% confidence intervals (shaded areas with dashed boundaries) for the distribution of times to relapse for treatment failures. (<bold>B</bold>) and (<bold>C</bold>) Arbitrary samples of the distribution of detection times for preventive and post-diagnostic interventions, respectively. The colour-code indicates the mean number of accumulated drivers over a period of 1 year. The rectangles at the top of <bold>B</bold> and the bottom of <bold>C</bold> shows the fifth and 95th percentiles, the blue circle indicates the median, and the red line is the mean. Parameters as in <xref ref-type="table" rid="tbl1">Table 1</xref>.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.06266.022">http://dx.doi.org/10.7554/eLife.06266.022</ext-link></p></caption></media></p><p><xref ref-type="fig" rid="fig5">Figure 5E,F</xref> shows the distributions of detection times for all numerical experiments. We see that when both non-relapse (<xref ref-type="fig" rid="fig5">Figure 5A</xref>) and relapse (<xref ref-type="fig" rid="fig5">Figure 5C</xref>) are taken into account for large cancer cell populations (1 million cells), treating preventively at levels beyond about 0.3% arrest per day increases median delays in detection times due to outright success (i.e., survival beyond 50 years) but has no effect on the lower 95th percentile (<xref ref-type="fig" rid="fig5">Figure 5E</xref>). (Although not shown, arrest beyond approximately 0.6% per day does not yield further gains). In contrast, post-diagnostic intervention improves only marginally beyond daily arrest levels of about 0.3% (<xref ref-type="fig" rid="fig5">Figure 5E</xref>). <xref ref-type="fig" rid="fig5">Figure 5F</xref> shows the corresponding results for smaller cancer cell populations (based on integrating the results in <xref ref-type="fig" rid="fig5">Figure 5B,D</xref>), whereby a high median probability of full success is obtained &gt;0.1% and <italic>&gt;</italic>0.3% daily arrest for prevention and post-diagnostic intervention, respectively (<xref ref-type="fig" rid="fig5">Figure 5F</xref>). Thus for both cell population levels, prevention generally results in better outcomes compared to post-diagnostic intervention.</p></sec></sec><sec id="s4" sec-type="discussion"><title>Discussion</title><p>MTD chemotherapies present numerous challenges, a major one being the selection of resistant phenotypes, which are possible precursors for relapse (<xref ref-type="bibr" rid="bib31">Gerlinger and Swanton, 2010</xref>). We mathematically and numerically investigated how the intensity of an anti-cancer measure, modelled as the arresting effect on a cancer cell population, resulted in success (i.e., either eradication or long-term tumour control) or failure (tumours growing beyond a threshold indicative of a life threatening cancer). Our central result is that beyond low impact thresholds—approximated by the Darwinian fitness of the subclone with the most driver mutations—little additional control is achieved when resistant subclones are present or likely to emerge during the long-term intervention assumed here.</p><p>We considered two contrasting scenarios. In the first, people at high risk of contracting a life threatening cancer make life-style changes or receive continuous, chemopreventive therapies, and in the second, more usual situation, a tumour is discovered and removed, and the patient treated with specific cytotoxic or cytostatic chemicals and/or with radiation. We found that, as expected, to achieve a given outcome, prevention requires smaller effects on cancer cell populations of a given size than do post-diagnostic interventions, the latter having smaller probabilities of complete cure and shorter times to tumour relapse. Inversely and importantly, for any given cell arrest level, prevention is, on average, superior to comparable post-diagnostic interventions, even when including cases where prevention initially fails, and resection and additional therapy are needed.</p><p>Specifically, based on empirical parameter estimates, we find that maximal long-term control occurs at surprisingly low daily levels of arrest. In the example where interventions target 1 million cancer cells, these levels are approximately 0.6% and 0.3% for preventive and post-diagnostic interventions, respectively. That the level is higher for preventive scenarios is because effective ‘cure’ (i.e., relapse does not occur during the 50 year period assumed in our numerical experiments) is possible, especially at cell arrest levels beyond 0.3%, whereas ‘cure’ is far less probable for post-diagnostic interventions. However, should prevention initially fail and a tumour be diagnosed and resected, any residual or metastatic cells are likely to contain more resistant clones than the corresponding situation for a post-diagnostic tumour. We stress that this latter result is contingent on our assumption that the same mutations (and mechanisms) are responsible for resistance to both preventive and post-diagnostic interventions. Should preventive and post-diagnostic measures differ substantially in their targets (and therefore resistance mechanisms), then evolved resistance to (failed) prevention could be irrelevant to the efficacy of subsequent traditional therapies.</p><p>Our results point to what is perhaps an underappreciated challenge in cancer control: low impact interventions risk being unable to control subclones with the most fitness-enhancing drivers, whereas high levels of arrest risk selecting for resistance (<xref ref-type="fig" rid="fig6">Figure 6</xref>). Future models should investigate these contingencies more extensively for alternative assumptions and a range of parameterizations for specific cancer types. Below, we discuss challenges to cancer management for both preventive and post-diagnostic scenarios.<fig id="fig6" position="float"><object-id pub-id-type="doi">10.7554/eLife.06266.023</object-id><label>Figure 6.</label><caption><title>Dependence of the median time for tumour detection on treatment intensity and pre-resistance levels.</title><p>Increasing treatment intensity selects against subclones with increasing numbers of drivers, whereas, regardless of treatment intensity, all resistant subclones with <italic>s</italic>(<italic>i</italic>+1) &gt; <italic>c</italic> increase in number. The solid lines illustrate how selection and the initial number of resistant cells in a treated tumour predict median detection times and associated resistance levels. Median detection times approach a horizontal asymptote at 100% resistance as treatment intensity increases, whereas if the resistant mutation were to be knocked out, then the vertical asymptote at σ<italic><sub>crit </sub></italic>= <italic>qs </italic>(where <italic>q </italic>is the number of drivers in the fastest growing subclone) would be approached instead for sufficiently small tumours. Asymptotes are shown as dashed lines. We illustrate three cases, each with an initial population of 100,000 identical cells (<italic>i </italic>= 0) and with one of three different initial numbers of resistant cells: 10, 100 or 1,000 (top to bottom lines). Other parameters as in <xref ref-type="table" rid="tbl1">Table 1</xref>.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.06266.023">http://dx.doi.org/10.7554/eLife.06266.023</ext-link></p></caption><graphic xlink:href="elife-06266-fig6-v2.tif"/></fig></p><sec id="s4-1"><title>Preventive interventions</title><p>Whereas primary prevention is becoming an increasingly significant approach in reducing risk of certain cancers (e.g., <xref ref-type="bibr" rid="bib14">Colditz and Bohlke, 2014</xref>), chemopreventive therapies are uncommon, despite empirical support for their effects (<xref ref-type="bibr" rid="bib72">William et al., 2009</xref>). Several theoretical and in vitro experimental studies indicate that chemoprevention can reduce risks of life threatening cancers. For example, Silva and colleagues (<xref ref-type="bibr" rid="bib65">Silva et al., 2012</xref>) parameterized computational models to show how low doses of verapamil and 2-deoxyglucose could be administered adaptively to promote longer tumour progression times. These drugs are thought to increase the costs of resistance and the competitive impacts of sensitive cells on resistant cancer cell subpopulations. However, some of the most promising results have come from studies employing non-steroidal anti-inflammatory drugs (NSAIDs), including experiments (<xref ref-type="bibr" rid="bib41">Ibrahim-Hashim et al., 2012</xref>), investigations of their molecular effects (<xref ref-type="bibr" rid="bib26">Galipeau et al., 2007</xref>; <xref ref-type="bibr" rid="bib47">Kostadinov et al., 2013</xref>), and their use (<xref ref-type="bibr" rid="bib15">Cuzick et al., 2015</xref>). For example, Ibrahim and co-workers (<xref ref-type="bibr" rid="bib41">Ibrahim-Hashim et al., 2012</xref>) studied the action of NSAIDs and specifically sodium bicarbonate in reducing prostate tumours in male TRAMP mice (i.e., an animal model of transgenic adenocarcinoma of the mouse prostate). They showed that mice commencing the treatment at 4 weeks of age had significantly smaller tumour masses, and that more survived to the end of the experiment than either the controls or those mice commencing the treatment at an older age. <xref ref-type="bibr" rid="bib47">Kostadinov et al. (2013)</xref> showed how NSAID use in a sample of people with Barrett's oesophagus is associated with reductions in somatic genomic abnormalities and their growth to detectable levels. It is noteworthy that it is not known to what extent reductions in cancer progression under NSAIDs are due to either cytotoxic or cytostatic effects or both. Although we do not explicitly model cytotoxic or cytostatic impacts, therapies curbing net growth rates but maintaining them at or above zero could be interpreted as resulting from the action of either cytotoxic and/or cytostatic processes. In contrast, therapies reducing net growth rates substantially below zero necessarily have a cytotoxic component. Our model, or modifications of it to explicitly include cytotoxic and cytostatic effects, could be used in future research to make predictions about optimal dose and start times to achieve acceptable levels of tumour control (or, e.g., the probability of a given tumour size and heterogeneity level by a given age).</p><p>Decisions whether or not to employ specific chemopreventive therapies carry with them the risk of a poorer outcome than would have been the case had another available strategy (or no treatment at all) been adopted (<xref ref-type="bibr" rid="bib20">Esserman et al., 2004</xref>). This issue is relevant to situations where alterations in life-style, removal or treatment of pre-cancerous lesions, or medications potentially result in unwanted side effects or induce new invasive neoplasms (e.g., <xref ref-type="bibr" rid="bib9">Berrington de Gonzalez et al., 2011</xref>). Chemopreventive management prior to clinical detection would be most appropriate for individuals with genetic predispositions, familial histories, elevated levels of specific biomarkers, or risk-associated behaviours or life-styles (<xref ref-type="bibr" rid="bib37">Hemminki and Li, 2004</xref>; <xref ref-type="bibr" rid="bib50">Lippman and Lee, 2006</xref>; <xref ref-type="bibr" rid="bib69">Sutcliffe et al., 2009</xref>; <xref ref-type="bibr" rid="bib72">William et al., 2009</xref>; <xref ref-type="bibr" rid="bib38">Hochberg et al., 2013</xref>). Importantly, our approach presupposes that the danger a nascent, growing tumour presents is proportional to its size and (implicitly, all else being equal) a person's age. Due caution is necessary in interpreting our results, since studies have argued that metastatic potential rather than tumour size may be a better predictor of future survival (<xref ref-type="bibr" rid="bib40">Hynes, 2003</xref>; <xref ref-type="bibr" rid="bib25">Foulkes et al., 2010</xref>; <xref ref-type="bibr" rid="bib64">Sethi and Kang, 2011</xref>). However, given the expectation that prevention typically confronts smaller, less heterogeneous neoplasms, which are less likely to have resistant clones and to have metastasised (<xref ref-type="bibr" rid="bib38">Hochberg et al., 2013</xref>; <xref ref-type="bibr" rid="bib32">Gerlinger et al., 2014</xref>), support our basic conclusion that prevention is generally a superior strategy in terms of cancer-free survival compared to post-diagnostic intervention.</p></sec><sec id="s4-2"><title>Post-diagnostic interventions</title><p>Over the past decade, several alternative approaches to MTD have been proposed, where the objective is to manage rather than eradicate tumours (e.g., <xref ref-type="bibr" rid="bib52">Maley et al., 2004</xref>; <xref ref-type="bibr" rid="bib45">Komarova and Wodarz, 2005</xref>; <xref ref-type="bibr" rid="bib30">Gatenby, 2009</xref>; <xref ref-type="bibr" rid="bib28">Gatenby et al., 2009a</xref>, <xref ref-type="bibr" rid="bib29">2009b</xref>; <xref ref-type="bibr" rid="bib24">Foo and Michor, 2010</xref>; <xref ref-type="bibr" rid="bib76">Jansen et al., 2015</xref>). Tumour management attempts to limit cancer growth, metastasis, and reduce the probability of obtaining resistance mutations through, for example, micro-environmental modification, or competition with non-resistant cancer cell populations or with healthy cells. These approaches usually involve clinically diagnosed cancers: either inoperable tumours or residual or metastatic cancers after tumour excision. In the former situation, tumours are typically large enough in size to contain numerous resistance mutations. In many, if not most, cases, these neoplasms will have metastasized, meaning greater variability both in terms of phenotypes and potential resistance to chemotherapies, and in penetrance of therapeutic molecules to targeted tumour cells (<xref ref-type="bibr" rid="bib44">Klein et al., 2002</xref>; <xref ref-type="bibr" rid="bib13">Byrne et al., 2005</xref>). In contrast, the latter situation involves smaller, residual, or metastatic cancer cell populations, composed of high frequencies of resistant variants or dormant cells (<xref ref-type="bibr" rid="bib44">Klein et al., 2002</xref>). According to our results, both scenarios are likely to involve populations with large numbers of accumulated driver mutations (or, although not considered in our study, fewer driver mutations but each with larger selective effect), which ostensibly contribute to the speed of relapse. Thus, management of clinically detected tumours need not only limit the proliferation and spread of refractory subpopulations but should also aim to control the growth of multi-driver subclones (<xref ref-type="fig" rid="fig5s2 fig5s3">Figure 5—figure supplements 2, 3</xref>). In other words, in addition to actual resistance mutations (<italic>j</italic> = 1), subclones with <italic>q</italic> drivers will be effectively resistant to therapeutic interventions if <italic>q s</italic> ≫ <italic>σ</italic> (<xref ref-type="fig" rid="fig6">Figure 6</xref>).</p><p>We therefore suggest that the frequency distribution of driver mutations and the distribution of resistant subclones within a heterogeneous cancer cell population could be used to instruct decisions of the time course of treatment levels, with the aims of curbing tumour growth, metastasis, and resistance. We found that tumours typically achieve several additional driver mutations by the time they reach detection (<xref ref-type="fig" rid="fig3">Figure 3A</xref>; <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>; <xref ref-type="fig" rid="fig5s2 fig5s3">Figure 5—figure supplements 2, 3</xref>), which approximates certain estimates (<xref ref-type="bibr" rid="bib68">Stratton et al., 2009</xref>) but falls short of others (<xref ref-type="bibr" rid="bib66">Sjoblom et al., 2006</xref>).</p></sec><sec id="s4-3"><title>Conclusion</title><p>Our results indicate that the two most important variables in determining therapeutic outcome are (1) the size of the initial cancer cell population (i.e., when prevention commences and/or post-diagnosis, following resection), (2) associated tumour heterogeneity in terms of accumulated drivers, and the presence of resistance phenotypes. This highlights the importance of biomarkers as accurate indicators of otherwise undetectable malignancies (<xref ref-type="bibr" rid="bib62">Roukos et al., 2007</xref>), and the accurate assessment of local or distant metastases (<xref ref-type="bibr" rid="bib59">Pantel et al., 1999</xref>). We suggest that if order-of-magnitude estimates of cell populations and intra-tumour heterogeneity are possible, then low dose, continuous, constant approaches could be established that lower and possibly minimize risks of the emergence of future, life-threatening cancers. According to our model, such options will generally be superior to more aggressive chemotherapies if therapeutic resistance is a risk factor.</p><p>The framework proposed here is sufficiently general to portray major events in different types of cancer with emphasis on solid tumours. However, some aspects of cancerous tumour growth are considered only implicitly, and further research is required to formulate more realistic models to include, for example, spatial aspects of tumour growth (<xref ref-type="bibr" rid="bib58">Orlando et al., 2013</xref>), competition/cooperation between different subclones (<xref ref-type="bibr" rid="bib46">Korolev et al., 2014</xref>), combinational (multidrug) resistance (<xref ref-type="bibr" rid="bib34">Gillet and Gottesman, 2010</xref>; <xref ref-type="bibr" rid="bib12">Bozic et al., 2013</xref>), drug-addiction, observed for example in certain melanomas (<xref ref-type="bibr" rid="bib16">Das Thakur et al., 2013</xref>), or advantageous resistant mutations, observed in some leukemias (<xref ref-type="bibr" rid="bib56">Michor et al., 2005</xref>). Moreover, future studies should investigate alternatives to the traditional post-diagnostic therapeutic scenarios considered here (e.g., molecularly targeted therapies [<xref ref-type="bibr" rid="bib75">Yap, 2015</xref>]). Our study nevertheless predicts that the main hurdle to post-diagnostic MTD interventions remains resistant subclones, since beyond minimal impacts on the order of 0.3% per day for the larger of the two residual or metastatic cell populations simulated here (which are still very small by clinical diagnostic standards—<italic>c</italic> 1 mm<sup>3</sup>), increased therapeutic intensity selects disproportionally for resistance and has negligible benefits in terms of delaying life-threatening cancers.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>The authors are grateful to Athena Aktipis, Daniel Fisher, Sylvain Gandon, Urszula Hibner, Natalia Komarova, Patrice Lassus, Carlo Maley, Ville Mustonen, Robert Noble and anonymous referees for comments. All calculations were made using programs, written in <italic>C</italic>, and the free, open-source statistical package <italic>R</italic> (<xref ref-type="bibr" rid="bib60">R Development Core Team, 2014</xref>). The colour palette for figures was adopted from ColorBrewer 2.0 (<xref ref-type="bibr" rid="bib2">Brewer and Harrower, 2013</xref>). Code for all calculations, and for producing all of the figures, is available at <ext-link ext-link-type="uri" xlink:href="http://tiny.cc/AkhmHoch15Scripts">http://tiny.cc/AkhmHoch15Scripts</ext-link> and can be used freely for non-commercial purposes. The work was made possible by the facilities of the Shared Hierarchical Academic Research Computing Network (SHARCNET:<ext-link ext-link-type="uri" xlink:href="http://www.sharcnet.ca">www.sharcnet.ca</ext-link>) and Compute/Calcul Canada. ARA was supported by CNRS Interdisciplinary postdoctoral program. MEH thanks ITMO ‘Physique Cancer’ (CanEvolve PC201306), ANR (EvoCan ANR-13-BSV7-0003-01) and PICS (PlCS05313) for financial support.</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>ARA, Performed computer simulations, Conception and design, Analysis and interpretation of data, Drafting or revising the article</p></fn><fn fn-type="con" id="con2"><p>MEH, Conception and design, Analysis and interpretation of data, Drafting or revising the article</p></fn></fn-group></sec><ref-list><title>References</title><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antal</surname><given-names>T</given-names></name><name><surname>Krapivsky</surname><given-names>PL</given-names></name></person-group><year>2011</year><article-title>Exact solution of a two-type branching process: models of tumor progression</article-title><source>Journal of Statistical Mechanics</source><volume>2011</volume><fpage>P08018</fpage><pub-id pub-id-type="doi">10.1088/1742-5468/2011/08/P08018</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="web"><person-group person-group-type="author"><name><surname>Assaf</surname><given-names>M</given-names></name></person-group><year>2010</year><article-title>Theory of large fluctuations in stochastic populations</article-title><comment>PhD thesis, Hebrew University of Jerusalem. <ext-link ext-link-type="uri" xlink:href="http://guava.physics.uiuc.edu/%7Eassaf/thesis.pdf">http://guava.physics.uiuc.edu/∼assaf/thesis.pdf</ext-link></comment></element-citation></ref><ref id="bib5"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Athreya</surname><given-names>KB</given-names></name><name><surname>Ney</surname><given-names>PE</given-names></name></person-group><year>1972</year><source>Branching processes</source><publisher-name>Springer-Verlag</publisher-name><publisher-loc>New York</publisher-loc></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baake</surname><given-names>E</given-names></name><name><surname>Wagner</surname><given-names>H</given-names></name></person-group><year>2001</year><article-title>Mutation-selection models solved exactly with methods of statistical mechanics</article-title><source>Genet Research</source><volume>78</volume><fpage>93</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1017/S0016672301005110</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beckman</surname><given-names>RA</given-names></name><name><surname>Schemmann</surname><given-names>GS</given-names></name><name><surname>Yeang</surname><given-names>CH</given-names></name></person-group><year>2012</year><article-title>Impact of genetic dynamics and single-cell heterogeneity on development of nonstandard personalized medicine strategies for cancer</article-title><source>Proceedings of the National Academy of Sciences of USA</source><volume>109</volume><fpage>14586</fpage><lpage>14591</lpage><pub-id pub-id-type="doi">10.1073/pnas.1203559109</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beerenwinkel</surname><given-names>N</given-names></name><name><surname>Schwarz</surname><given-names>RF</given-names></name><name><surname>Gerstung</surname><given-names>M</given-names></name><name><surname>Markowetz</surname><given-names>F</given-names></name></person-group><year>2015</year><article-title>Cancer evolution: mathematical models and computational inference</article-title><source>Systematic Biology</source><volume>64</volume><fpage>e1</fpage><lpage>e25</lpage><pub-id pub-id-type="doi">10.1093/sysbio/syu081</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berrington de Gonzalez</surname><given-names>A</given-names></name><name><surname>Curtis</surname><given-names>RE</given-names></name><name><surname>Kry</surname><given-names>SF</given-names></name><name><surname>Gilbert</surname><given-names>E</given-names></name><name><surname>Lamart</surname><given-names>S</given-names></name><name><surname>Berg</surname><given-names>CD</given-names></name><name><surname>Stovall</surname><given-names>M</given-names></name><name><surname>Ron</surname><given-names>E</given-names></name></person-group><year>2011</year><article-title>Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries</article-title><source>The Lancet Oncology</source><volume>12</volume><fpage>353</fpage><lpage>360</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(11)70061-4</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bissell</surname><given-names>MJ</given-names></name><name><surname>Hines</surname><given-names>WC</given-names></name></person-group><year>2011</year><article-title>Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression</article-title><source>Nature Medicine</source><volume>17</volume><fpage>320</fpage><lpage>329</lpage><pub-id pub-id-type="doi">10.1038/nm.2328</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bozic</surname><given-names>I</given-names></name><name><surname>Antal</surname><given-names>T</given-names></name><name><surname>Ohtsuki</surname><given-names>H</given-names></name><name><surname>Carter</surname><given-names>H</given-names></name><name><surname>Kim</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Karchin</surname><given-names>R</given-names></name><name><surname>Kinzler</surname><given-names>KW</given-names></name><name><surname>Vogelstein</surname><given-names>B</given-names></name><name><surname>Nowak</surname><given-names>MA</given-names></name></person-group><year>2010</year><article-title>Accumulation of driver and passenger mutations during tumor progression</article-title><source>Proceedings of the National Academy of Sciences of USA</source><volume>107</volume><fpage>18545</fpage><lpage>18550</lpage><pub-id pub-id-type="doi">10.1073/pnas.1010978107</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bozic</surname><given-names>I</given-names></name><name><surname>Reiter</surname><given-names>JG</given-names></name><name><surname>Allen</surname><given-names>B</given-names></name><name><surname>Antal</surname><given-names>T</given-names></name><name><surname>Chatterjee</surname><given-names>K</given-names></name><name><surname>Shah</surname><given-names>P</given-names></name><name><surname>Moon</surname><given-names>YS</given-names></name><name><surname>Yaqubie</surname><given-names>A</given-names></name><name><surname>Kelly</surname><given-names>N</given-names></name><name><surname>Le</surname><given-names>DT</given-names></name><name><surname>Lipson</surname><given-names>EJ</given-names></name><name><surname>Chapman</surname><given-names>PB</given-names></name><name><surname>Diaz</surname><given-names>LAJ</given-names></name><name><surname>Vogelstein</surname><given-names>B</given-names></name><name><surname>Nowak</surname><given-names>MA</given-names></name></person-group><year>2013</year><article-title>Evolutionary dynamics of cancer in response to targeted combination therapy</article-title><source>eLife</source><volume>2</volume><fpage>e00747</fpage><pub-id pub-id-type="doi">10.7554/eLife.00747</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Brewer</surname><given-names>C</given-names></name><name><surname>Harrower</surname><given-names>M</given-names></name></person-group><year>2013</year><source>ColourBrew 2.0: color advice for cartography</source><comment>Pennsylvania State University. <ext-link ext-link-type="uri" xlink:href="http://colorbrewer2.org">http://colorbrewer2.org</ext-link>. Accessed 21.04.2014</comment></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Byrne</surname><given-names>AM</given-names></name><name><surname>Bouchier-Hayes</surname><given-names>DJ</given-names></name><name><surname>Harmey</surname><given-names>JH</given-names></name></person-group><year>2005</year><article-title>Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF)</article-title><source>Journal of Cellular and Molecular Medicine</source><volume>9</volume><fpage>777</fpage><lpage>794</lpage><pub-id pub-id-type="doi">10.1111/j.1582-4934.2005.tb00379.x</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colditz</surname><given-names>GA</given-names></name><name><surname>Bohlke</surname><given-names>K</given-names></name></person-group><year>2014</year><article-title>Priorities for the primary prevention of breast cancer</article-title><source>CA</source><volume>64</volume><fpage>186</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.3322/caac.21225</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cuzick</surname><given-names>J</given-names></name><name><surname>Thorat</surname><given-names>MA</given-names></name><name><surname>Bosetti</surname><given-names>C</given-names></name><name><surname>Brown</surname><given-names>PH</given-names></name><name><surname>Burn</surname><given-names>J</given-names></name><name><surname>Cook</surname><given-names>NR</given-names></name><name><surname>Ford</surname><given-names>LG</given-names></name><name><surname>Jacobs</surname><given-names>EJ</given-names></name><name><surname>Jankowski</surname><given-names>JA</given-names></name><name><surname>La Vecchia</surname><given-names>C</given-names></name><name><surname>Law</surname><given-names>M</given-names></name><name><surname>Meyskens</surname><given-names>F</given-names></name><name><surname>Rothwell</surname><given-names>PM</given-names></name><name><surname>Senn</surname><given-names>HJ</given-names></name><name><surname>Umar</surname><given-names>A</given-names></name></person-group><year>2015</year><article-title>Estimates of benefits and harms of prophylactic use of aspirin in the general population</article-title><source>Annals of Oncology</source><volume>26</volume><fpage>47</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdu225</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Das Thakur</surname><given-names>M</given-names></name><name><surname>Salangsang</surname><given-names>F</given-names></name><name><surname>Landman</surname><given-names>AS</given-names></name><name><surname>Sellers</surname><given-names>WR</given-names></name><name><surname>Pryer</surname><given-names>NK</given-names></name><name><surname>Levesque</surname><given-names>MP</given-names></name><name><surname>Dummer</surname><given-names>R</given-names></name><name><surname>McMahon</surname><given-names>M</given-names></name><name><surname>Stuart</surname><given-names>DD</given-names></name></person-group><year>2013</year><article-title>Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance</article-title><source>Nature</source><volume>494</volume><fpage>251</fpage><lpage>255</lpage><pub-id pub-id-type="doi">10.1038/nature11814</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doll</surname><given-names>R</given-names></name><name><surname>Peto</surname><given-names>R</given-names></name></person-group><year>1976</year><article-title>Mortality in relation to smoking: 20 years' observations on male British doctors</article-title><source>British Medical Journal</source><volume>2</volume><fpage>1525</fpage><lpage>1536</lpage><pub-id pub-id-type="doi">10.1136/bmj.2.6051.1525</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elgart</surname><given-names>V</given-names></name><name><surname>Kamenev</surname><given-names>A</given-names></name></person-group><year>2004</year><article-title>Rare event statistics in reaction-diffusion systems</article-title><source>Physical Review. E, Statistical, Nonlinear, and Soft Matter Physics</source><volume>70</volume><fpage>041106</fpage><pub-id pub-id-type="doi">10.1103/PhysRevE.70.041106</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esserman</surname><given-names>L</given-names></name><name><surname>Sepucha</surname><given-names>K</given-names></name><name><surname>Ozanne</surname><given-names>E</given-names></name><name><surname>Hwang</surname><given-names>ES</given-names></name></person-group><year>2004</year><article-title>Applying the neoadjuvant paradigm to ductal carcinoma in situ</article-title><source>Annals of Surgical Oncology</source><volume>11</volume><fpage>S28</fpage><lpage>S36</lpage><pub-id pub-id-type="doi">10.1007/BF02524793</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Etzioni</surname><given-names>R</given-names></name><name><surname>Urban</surname><given-names>N</given-names></name><name><surname>Ramsey</surname><given-names>S</given-names></name><name><surname>McIntosh</surname><given-names>M</given-names></name><name><surname>Schwartz</surname><given-names>S</given-names></name><name><surname>Reid</surname><given-names>B</given-names></name><name><surname>Radich</surname><given-names>J</given-names></name><name><surname>Anderson</surname><given-names>G</given-names></name><name><surname>Hartwell</surname><given-names>L</given-names></name></person-group><year>2003</year><article-title>The case for early detection</article-title><source>Nature Reviews. Cancer</source><volume>3</volume><fpage>243</fpage><lpage>252</lpage><pub-id pub-id-type="doi">10.1038/nrc1041</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fischer</surname><given-names>A</given-names></name><name><surname>Vázquez-García</surname><given-names>I</given-names></name><name><surname>Mustonen</surname><given-names>V</given-names></name></person-group><year>2015</year><article-title>The value of monitoring to control evolving populations</article-title><source>Proceedings of the National Academy of Sciences of USA</source><volume>112</volume><fpage>1007</fpage><lpage>1012</lpage><pub-id pub-id-type="doi">10.1073/pnas.1409403112</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foo</surname><given-names>J</given-names></name><name><surname>Michor</surname><given-names>F</given-names></name></person-group><year>2009</year><article-title>Evolution of resistance to targeted anti-cancer therapies during continuous and pulsed administration strategies</article-title><source>PLOS Computational Biology</source><volume>5</volume><fpage>e1000557</fpage><pub-id pub-id-type="doi">10.1371/journal.pcbi.1000557</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foo</surname><given-names>J</given-names></name><name><surname>Michor</surname><given-names>F</given-names></name></person-group><year>2010</year><article-title>Evolution of resistance to anti-cancer therapy during general dosing schedules</article-title><source>Journal of Theoretical Biology</source><volume>263</volume><fpage>179</fpage><lpage>188</lpage><pub-id pub-id-type="doi">10.1016/j.jtbi.2009.11.022</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foulkes</surname><given-names>WD</given-names></name><name><surname>Smith</surname><given-names>IE</given-names></name><name><surname>Reis-Filho</surname><given-names>JS</given-names></name></person-group><year>2010</year><article-title>Triple-negative breast cancer</article-title><source>The New England Journal of Medicine</source><volume>363</volume><fpage>1938</fpage><lpage>1948</lpage><pub-id pub-id-type="doi">10.1056/NEJMra1001389</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galipeau</surname><given-names>PC</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Blount</surname><given-names>PL</given-names></name><name><surname>Maley</surname><given-names>CC</given-names></name><name><surname>Sanchez</surname><given-names>CA</given-names></name><name><surname>Odze</surname><given-names>RD</given-names></name><name><surname>Ayub</surname><given-names>K</given-names></name><name><surname>Rabinovitch</surname><given-names>PS</given-names></name><name><surname>Vaughan</surname><given-names>TL</given-names></name><name><surname>Reid</surname><given-names>BJ</given-names></name></person-group><year>2007</year><article-title>NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma</article-title><source>PLOS Medicine</source><volume>4</volume><fpage>e67</fpage><pub-id pub-id-type="doi">10.1371/journal.pmed.0040067</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Gardiner</surname><given-names>CW</given-names></name></person-group><year>2004</year><source>Handbook of stochastic methods</source><edition>3rd ed</edition><publisher-name>Springer</publisher-name><publisher-loc>New York</publisher-loc></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gatenby</surname><given-names>RA</given-names></name></person-group><year>2009</year><article-title>A change of strategy in the war on cancer</article-title><source>Nature</source><volume>459</volume><fpage>508</fpage><lpage>509</lpage><pub-id pub-id-type="doi">10.1038/459508a</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gatenby</surname><given-names>RA</given-names></name><name><surname>Brown</surname><given-names>JS</given-names></name><name><surname>Vincent</surname><given-names>T</given-names></name></person-group><year>2009a</year><article-title>Lessons from applied ecology: cancer control using an evolutionary double bind</article-title><source>Cancer Research</source><volume>69</volume><fpage>7499</fpage><lpage>7502</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-09-1354</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gatenby</surname><given-names>RA</given-names></name><name><surname>Silva</surname><given-names>AS</given-names></name><name><surname>Gillies</surname><given-names>RJ</given-names></name><name><surname>Frieden</surname><given-names>BR</given-names></name></person-group><year>2009b</year><article-title>Adaptive therapy</article-title><source>Cancer Research</source><volume>69</volume><fpage>4894</fpage><lpage>4903</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-08-3658</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerlinger</surname><given-names>M</given-names></name><name><surname>Swanton</surname><given-names>C</given-names></name></person-group><year>2010</year><article-title>How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine</article-title><source>British Journal of Cancer</source><volume>103</volume><fpage>1139</fpage><lpage>1143</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6605912</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerlinger</surname><given-names>M</given-names></name><name><surname>McGranahan</surname><given-names>N</given-names></name><name><surname>Dewhurst</surname><given-names>SM</given-names></name><name><surname>Burrell</surname><given-names>RA</given-names></name><name><surname>Tomlinson</surname><given-names>I</given-names></name><name><surname>Swanton</surname><given-names>C</given-names></name></person-group><year>2014</year><article-title>Cancer: evolution within a lifetime</article-title><source>Annual Review of Genetics</source><volume>48</volume><fpage>215</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1146/annurev-genet-120213-092314</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerstung</surname><given-names>M</given-names></name><name><surname>Eriksson</surname><given-names>N</given-names></name><name><surname>Lin</surname><given-names>J</given-names></name><name><surname>Vogelstein</surname><given-names>B</given-names></name><name><surname>Beerenwinkel</surname><given-names>N</given-names></name></person-group><year>2011</year><article-title>The temporal order of genetic and pathway alterations in tumorigenesis</article-title><source>PLOS ONE</source><volume>6</volume><fpage>e27136</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0027136</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gillet</surname><given-names>JP</given-names></name><name><surname>Gottesman</surname><given-names>MM</given-names></name></person-group><year>2010</year><article-title>Mechanisms of multidrug resistance in cancer</article-title><source>Methods in Molecular Biology</source><volume>596</volume><fpage>47</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1007/978-1-60761-416-6_4</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gillies</surname><given-names>RJ</given-names></name><name><surname>Flowers</surname><given-names>CI</given-names></name><name><surname>Drukteinis</surname><given-names>JS</given-names></name><name><surname>Gatenby</surname><given-names>RA</given-names></name></person-group><year>2012</year><article-title>A unifying theory of carcinogenesis, and why targeted therapy doesn't work</article-title><source>European Journal of Radiology</source><volume>81</volume><supplement>(Suppl 1)</supplement><fpage>S48</fpage><lpage>S50</lpage><pub-id pub-id-type="doi">10.1016/S0720-048X(12)70018-9</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greaves</surname><given-names>M</given-names></name></person-group><year>2014</year><article-title>Does everyone develop covert cancer?</article-title><source>Nature Reviews. Cancer</source><volume>14</volume><fpage>209</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.1038/nrc3703</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hemminki</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>X</given-names></name></person-group><year>2004</year><article-title>Familial risk in testicular cancer as a clue to a heritable and environmental aetiology</article-title><source>British Journal of Cancer</source><volume>90</volume><fpage>1765</fpage><lpage>1770</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6601714</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hochberg</surname><given-names>ME</given-names></name><name><surname>Thomas</surname><given-names>F</given-names></name><name><surname>Assenat</surname><given-names>E</given-names></name><name><surname>Hibner</surname><given-names>U</given-names></name></person-group><year>2013</year><article-title>Preventive evolutionary medicine of cancers</article-title><source>Evolutionary Applications</source><volume>6</volume><fpage>134</fpage><lpage>143</lpage><pub-id pub-id-type="doi">10.1111/eva.12033</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huijben</surname><given-names>S</given-names></name><name><surname>Bell</surname><given-names>AS</given-names></name><name><surname>Sim</surname><given-names>DG</given-names></name><name><surname>Tomasello</surname><given-names>D</given-names></name><name><surname>Mideo</surname><given-names>N</given-names></name><name><surname>Day</surname><given-names>T</given-names></name><name><surname>Read</surname><given-names>AF</given-names></name></person-group><year>2013</year><article-title>Aggressive chemotherapy and the selection of drug resistant pathogens</article-title><source>PLOS Pathogens</source><volume>9</volume><fpage>e1003578</fpage><pub-id pub-id-type="doi">10.1371/journal.ppat.1003578</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hynes</surname><given-names>RO</given-names></name></person-group><year>2003</year><article-title>Metastatic potential: generic predisposition of the primary tumor or rare, metastatic variants-or both?</article-title><source>Cell</source><volume>113</volume><fpage>821</fpage><lpage>823</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(03)00468-9</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ibrahim-Hashim</surname><given-names>A</given-names></name><name><surname>Cornnell</surname><given-names>HH</given-names></name><name><surname>Abrahams</surname><given-names>D</given-names></name><name><surname>Lloyd</surname><given-names>M</given-names></name><name><surname>Bui</surname><given-names>M</given-names></name><name><surname>Gillies</surname><given-names>RJ</given-names></name><name><surname>Gatenby</surname><given-names>RA</given-names></name></person-group><year>2012</year><article-title>Systemic buffers inhibit carcinogenesis in TRAMP mice</article-title><source>The Journal of Urology</source><volume>188</volume><fpage>624</fpage><lpage>631</lpage><pub-id pub-id-type="doi">10.1016/j.juro.2012.03.113</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwasa</surname><given-names>Y</given-names></name><name><surname>Nowak</surname><given-names>MA</given-names></name><name><surname>Michor</surname><given-names>F</given-names></name></person-group><year>2006</year><article-title>Evolution of resistance during clonal expansion</article-title><source>Genetics</source><volume>172</volume><fpage>2557</fpage><lpage>2566</lpage><pub-id pub-id-type="doi">10.1534/genetics.105.049791</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jansen</surname><given-names>G</given-names></name><name><surname>Gatenby</surname><given-names>R</given-names></name><name><surname>Aktipis</surname><given-names>CA</given-names></name></person-group><year>2015</year><article-title>Opinion: Control vs. eradication: Applying infectious disease treatment strategies to cancer</article-title><source>Proceedings of the National Academy of Sciences USA</source><volume>112</volume><fpage>937</fpage><lpage>938</lpage><pub-id pub-id-type="doi">10.1073/pnas.1420297111</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kessler</surname><given-names>DA</given-names></name><name><surname>Levine</surname><given-names>H</given-names></name></person-group><year>2013</year><article-title>Large population solution of the stochastic Luria-Delbruck evolution model</article-title><source>Proceedings of the National Academy of Sciences of USA</source><volume>110</volume><fpage>11682</fpage><lpage>11687</lpage><pub-id pub-id-type="doi">10.1073/pnas.1309667110</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>CA</given-names></name><name><surname>Blankenstein</surname><given-names>TJF</given-names></name><name><surname>Schmidt-Kittler</surname><given-names>O</given-names></name><name><surname>Petronio</surname><given-names>M</given-names></name><name><surname>Polzer</surname><given-names>B</given-names></name><name><surname>Stoecklein</surname><given-names>NH</given-names></name><name><surname>Riethmuller</surname><given-names>G</given-names></name></person-group><year>2002</year><article-title>Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer</article-title><source>Lancet</source><volume>360</volume><fpage>683</fpage><lpage>689</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(02)09838-0</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Komarova</surname><given-names>NL</given-names></name><name><surname>Wodarz</surname><given-names>D</given-names></name></person-group><year>2005</year><article-title>Drug resistance in cancer: principles of emergence and prevention</article-title><source>Proceedings of the National Academy of Sciences of USA</source><volume>102</volume><fpage>9714</fpage><lpage>9719</lpage><pub-id pub-id-type="doi">10.1073/pnas.0501870102</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Korolev</surname><given-names>KS</given-names></name><name><surname>Xavier</surname><given-names>JB</given-names></name><name><surname>Gore</surname><given-names>J</given-names></name></person-group><year>2014</year><article-title>Turning ecology and evolution against cancer</article-title><source>Nature Reviews. Cancer</source><volume>14</volume><fpage>371</fpage><lpage>380</lpage><pub-id pub-id-type="doi">10.1038/nrc3712</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kostadinov</surname><given-names>RL</given-names></name><name><surname>Kuhner</surname><given-names>MK</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Sanchez</surname><given-names>CA</given-names></name><name><surname>Galipeau</surname><given-names>PC</given-names></name><name><surname>Paulson</surname><given-names>TG</given-names></name><name><surname>Sather</surname><given-names>CL</given-names></name><name><surname>Srivastava</surname><given-names>A</given-names></name><name><surname>Odze</surname><given-names>RD</given-names></name><name><surname>Blount</surname><given-names>PL</given-names></name><name><surname>Vaughan</surname><given-names>TL</given-names></name><name><surname>Reid</surname><given-names>BJ</given-names></name><name><surname>Maley</surname><given-names>CC</given-names></name></person-group><year>2013</year><article-title>NSAIDs modulate clonal evolution in Barrett's esophagus</article-title><source>PLOS Genetics</source><volume>9</volume><fpage>e1003553</fpage><pub-id pub-id-type="doi">10.1371/journal.pgen.1003553</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kouyos</surname><given-names>RD</given-names></name><name><surname>Metcalf</surname><given-names>CJE</given-names></name><name><surname>Birger</surname><given-names>R</given-names></name><name><surname>Klein</surname><given-names>EY</given-names></name><name><surname>Abel zur Wiesch</surname><given-names>P</given-names></name><name><surname>Ankomah</surname><given-names>P</given-names></name><name><surname>Arinaminpathy</surname><given-names>N</given-names></name><name><surname>Bogich</surname><given-names>TL</given-names></name><name><surname>Bonhoeffer</surname><given-names>S</given-names></name><name><surname>Brower</surname><given-names>C</given-names></name><name><surname>Chi-Johnston</surname><given-names>G</given-names></name><name><surname>Cohen</surname><given-names>T</given-names></name><name><surname>Day</surname><given-names>T</given-names></name><name><surname>Greenhouse</surname><given-names>B</given-names></name><name><surname>Huijben</surname><given-names>S</given-names></name><name><surname>Metlay</surname><given-names>J</given-names></name><name><surname>Mideo</surname><given-names>N</given-names></name><name><surname>Pollitt</surname><given-names>LC</given-names></name><name><surname>Read</surname><given-names>AF</given-names></name><name><surname>Smith</surname><given-names>DL</given-names></name><name><surname>Standley</surname><given-names>C</given-names></name><name><surname>Wale</surname><given-names>N</given-names></name><name><surname>Grenfell</surname><given-names>B</given-names></name></person-group><year>2014</year><article-title>The path of least resistance: aggressive or moderate treatment?</article-title><source>Proceedings. Biological Sciences/The Royal Society</source><volume>281</volume><fpage>20140566</fpage><pub-id pub-id-type="doi">10.1098/rspb.2014.0566</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Krapivsky</surname><given-names>PL</given-names></name><name><surname>Redner</surname><given-names>S</given-names></name><name><surname>Ben-Naim</surname><given-names>EA</given-names></name></person-group><year>2010</year><source>Kinetic view of statistical physics</source><publisher-loc>Cambridge</publisher-loc><publisher-name>Cambridge University Press</publisher-name></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lippman</surname><given-names>SM</given-names></name><name><surname>Lee</surname><given-names>JJ</given-names></name></person-group><year>2006</year><article-title>Reducing the “risk” of chemoprevention: defining and targeting high risk—2005 AACR Cancer Research and Prevention Foundation Award Lecture</article-title><source>Cancer Research</source><volume>66</volume><fpage>2893</fpage><lpage>2903</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-4573</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lorz</surname><given-names>A</given-names></name><name><surname>Lorenzi</surname><given-names>T</given-names></name><name><surname>Hochberg</surname><given-names>ME</given-names></name><name><surname>Clairambault</surname><given-names>J</given-names></name><name><surname>Perthame</surname><given-names>B</given-names></name></person-group><year>2013</year><article-title>Populational adaptive evolution, chemotherapeutic resistance and multiple anti-cancer therapies</article-title><source>ESAIM</source><volume>47</volume><fpage>377</fpage><lpage>399</lpage><pub-id pub-id-type="doi">10.1051/m2an/2012031</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maley</surname><given-names>CC</given-names></name><name><surname>Reid</surname><given-names>BJ</given-names></name><name><surname>Forrest</surname><given-names>S</given-names></name></person-group><year>2004</year><article-title>Cancer prevention strategies that address the evolutionary dynamics of neoplastic cells: simulating benign cell boosters and selection for chemosensitivity</article-title><source>Cancer Epidemiology, Biomarkers &amp; Prevention</source><volume>13</volume><fpage>1375</fpage><lpage>1384</lpage></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marusyk</surname><given-names>A</given-names></name><name><surname>Almendro</surname><given-names>V</given-names></name><name><surname>Polyak</surname><given-names>K</given-names></name></person-group><year>2012</year><article-title>Intra-tumour heterogeneity: a looking glass for cancer?</article-title><source>Nature Reviews. Cancer</source><volume>12</volume><fpage>323</fpage><lpage>334</lpage><pub-id pub-id-type="doi">10.1038/nrc3261</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McFarland</surname><given-names>CD</given-names></name><name><surname>Korolev</surname><given-names>KS</given-names></name><name><surname>Kryukov</surname><given-names>GV</given-names></name><name><surname>Sunyaev</surname><given-names>SR</given-names></name><name><surname>Mirny</surname><given-names>LA</given-names></name></person-group><year>2013</year><article-title>Impact of deleterious passenger mutations on cancer progression</article-title><source>Proceedings of the National Academy of Sciences of USA</source><volume>110</volume><fpage>2910</fpage><lpage>2915</lpage><pub-id pub-id-type="doi">10.1073/pnas.1213968110</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Melikyan</surname><given-names>AA</given-names></name></person-group><year>1998</year><source>Generalized characteristics of first order partial differential equations</source><publisher-loc>Boston</publisher-loc><publisher-name>Birkhäuser</publisher-name></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michor</surname><given-names>F</given-names></name><name><surname>Hughes</surname><given-names>TP</given-names></name><name><surname>Iwasa</surname><given-names>Y</given-names></name><name><surname>Branford</surname><given-names>S</given-names></name><name><surname>Shah</surname><given-names>NP</given-names></name><name><surname>Sawyers</surname><given-names>CL</given-names></name><name><surname>Nowak</surname><given-names>MA</given-names></name></person-group><year>2005</year><article-title>Dynamics of chronic myeloid leukaemia</article-title><source>Nature</source><volume>435</volume><fpage>1267</fpage><lpage>1270</lpage><pub-id pub-id-type="doi">10.1038/nature03669</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Orlando</surname><given-names>PA</given-names></name><name><surname>Gatenby</surname><given-names>RA</given-names></name><name><surname>Brown</surname><given-names>JS</given-names></name></person-group><year>2013</year><article-title>Tumor evolution in space: the effects of competition colonization tradeoffs on tumor invasion dynamics</article-title><source>Frontiers in Oncology</source><volume>3</volume><fpage>45</fpage><pub-id pub-id-type="doi">10.3389/fonc.2013.00045</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pantel</surname><given-names>K</given-names></name><name><surname>Cote</surname><given-names>RJ</given-names></name><name><surname>Fodstad</surname><given-names>O</given-names></name></person-group><year>1999</year><article-title>Detection and clinical importance of micrometastatic disease</article-title><source>Journal of the National Cancer Institute</source><volume>91</volume><fpage>1113</fpage><lpage>1124</lpage><pub-id pub-id-type="doi">10.1093/jnci/91.13.1113</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="software"><person-group person-group-type="author"><collab>R Development Core Team</collab></person-group><year>2014</year><source>R project for statistical computing</source><edition>R package version 2.15.3</edition><ext-link ext-link-type="uri" xlink:href="http://www.r-project.org/">http://www.r-project.org/</ext-link></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reiter</surname><given-names>JG</given-names></name><name><surname>Bozic</surname><given-names>I</given-names></name><name><surname>Allen</surname><given-names>B</given-names></name><name><surname>Chatterjee</surname><given-names>K</given-names></name><name><surname>Nowak</surname><given-names>MA</given-names></name></person-group><year>2013</year><article-title>The effect of one additional driver mutation on tumor progression</article-title><source>Evolutionary Applications</source><volume>6</volume><fpage>34</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1111/eva.12020</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roukos</surname><given-names>DH</given-names></name><name><surname>Murray</surname><given-names>S</given-names></name><name><surname>Briasoulis</surname><given-names>E</given-names></name></person-group><year>2007</year><article-title>Molecular genetic tools shape a roadmap towards a more accurate prognostic prediction and personalized management of cancer</article-title><source>Cancer Biology &amp; Therapy</source><volume>6</volume><fpage>308</fpage><lpage>312</lpage><pub-id pub-id-type="doi">10.4161/cbt.6.3.3994</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saakian</surname><given-names>DB</given-names></name><name><surname>Hu</surname><given-names>CK</given-names></name></person-group><year>2006</year><article-title>Exact solution of the Eigen model with general fitness functions and degradation rates</article-title><source>Proceedings of the National Academy of Sciences of USA</source><volume>103</volume><fpage>4935</fpage><lpage>4939</lpage><pub-id pub-id-type="doi">10.1073/pnas.0504924103</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sethi</surname><given-names>N</given-names></name><name><surname>Kang</surname><given-names>Y</given-names></name></person-group><year>2011</year><article-title>Unravelling the complexity of metastasis—molecular understanding and targeted therapies</article-title><source>Nature Reviews. Cancer</source><volume>11</volume><fpage>735</fpage><lpage>748</lpage><pub-id pub-id-type="doi">10.1038/nrc3125</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silva</surname><given-names>AS</given-names></name><name><surname>Kam</surname><given-names>Y</given-names></name><name><surname>Khin</surname><given-names>ZP</given-names></name><name><surname>Minton</surname><given-names>SE</given-names></name><name><surname>Gillies</surname><given-names>RJ</given-names></name><name><surname>Gatenby</surname><given-names>RA</given-names></name></person-group><year>2012</year><article-title>Evolutionary approaches to prolong progression-free survival in breast cancer</article-title><source>Cancer Research</source><volume>72</volume><fpage>6362</fpage><lpage>6370</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-12-2235</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sjoblom</surname><given-names>T</given-names></name><name><surname>Jones</surname><given-names>S</given-names></name><name><surname>Wood</surname><given-names>LD</given-names></name><name><surname>Parsons</surname><given-names>DW</given-names></name><name><surname>Lin</surname><given-names>J</given-names></name><name><surname>Barber</surname><given-names>TD</given-names></name><name><surname>Mandelker</surname><given-names>D</given-names></name><name><surname>Leary</surname><given-names>RJ</given-names></name><name><surname>Ptak</surname><given-names>J</given-names></name><name><surname>Silliman</surname><given-names>N</given-names></name><name><surname>Szabo</surname><given-names>S</given-names></name><name><surname>Buckhaults</surname><given-names>P</given-names></name><name><surname>Farrell</surname><given-names>C</given-names></name><name><surname>Meeh</surname><given-names>P</given-names></name><name><surname>Markowitz</surname><given-names>SD</given-names></name><name><surname>Willis</surname><given-names>J</given-names></name><name><surname>Dawson</surname><given-names>D</given-names></name><name><surname>Willson</surname><given-names>JKV</given-names></name><name><surname>Gazdar</surname><given-names>AF</given-names></name><name><surname>Hartigan</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Parmigiani</surname><given-names>G</given-names></name><name><surname>Park</surname><given-names>BH</given-names></name><name><surname>Bachman</surname><given-names>KE</given-names></name><name><surname>Papadopoulos</surname><given-names>N</given-names></name><name><surname>Vogelstein</surname><given-names>B</given-names></name><name><surname>Kinzler</surname><given-names>KW</given-names></name><name><surname>Velculescu</surname><given-names>VE</given-names></name></person-group><year>2006</year><article-title>The consensus coding sequences of human breast and colorectal cancers</article-title><source>Science</source><volume>314</volume><fpage>268</fpage><lpage>274</lpage><pub-id pub-id-type="doi">10.1126/science.1133427</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steward</surname><given-names>WP</given-names></name><name><surname>Brown</surname><given-names>K</given-names></name></person-group><year>2013</year><article-title>Cancer chemoprevention: a rapidly evolving field</article-title><source>British Journal of Cancer</source><volume>109</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1038/bjc.2013.280</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stratton</surname><given-names>MR</given-names></name><name><surname>Campbell</surname><given-names>PJ</given-names></name><name><surname>Futreal</surname><given-names>PA</given-names></name></person-group><year>2009</year><article-title>The cancer genome</article-title><source>Nature</source><volume>458</volume><fpage>719</fpage><lpage>724</lpage><pub-id pub-id-type="doi">10.1038/nature07943</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sutcliffe</surname><given-names>P</given-names></name><name><surname>Hummel</surname><given-names>S</given-names></name><name><surname>Simpson</surname><given-names>E</given-names></name><name><surname>Young</surname><given-names>T</given-names></name><name><surname>Rees</surname><given-names>A</given-names></name><name><surname>Wilkinson</surname><given-names>A</given-names></name><name><surname>Hamdy</surname><given-names>F</given-names></name><name><surname>Clarke</surname><given-names>N</given-names></name><name><surname>Staffurth</surname><given-names>J</given-names></name></person-group><year>2009</year><article-title>Use of classical and novel biomarkers as prognostic risk factors for localised prostate cancer: a systematic review</article-title><source>Health Technology Assessment</source><volume>13</volume><fpage>1</fpage><lpage>219</lpage><pub-id pub-id-type="doi">10.3310/hta13050</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turke</surname><given-names>AB</given-names></name><name><surname>Zejnullahu</surname><given-names>K</given-names></name><name><surname>Wu</surname><given-names>YL</given-names></name><name><surname>Song</surname><given-names>Y</given-names></name><name><surname>Dias-Santagata</surname><given-names>D</given-names></name><name><surname>Lifshits</surname><given-names>E</given-names></name><name><surname>Toschi</surname><given-names>L</given-names></name><name><surname>Rogers</surname><given-names>A</given-names></name><name><surname>Mok</surname><given-names>T</given-names></name><name><surname>Sequist</surname><given-names>L</given-names></name><name><surname>Lindeman</surname><given-names>NI</given-names></name><name><surname>Murphy</surname><given-names>C</given-names></name><name><surname>Akhavanfard</surname><given-names>S</given-names></name><name><surname>Yeap</surname><given-names>BY</given-names></name><name><surname>Xiao</surname><given-names>Y</given-names></name><name><surname>Capelletti</surname><given-names>M</given-names></name><name><surname>Iafrate</surname><given-names>AJ</given-names></name><name><surname>Lee</surname><given-names>C</given-names></name><name><surname>Christensen</surname><given-names>JG</given-names></name><name><surname>Engelman</surname><given-names>JA</given-names></name><name><surname>Janne</surname><given-names>PA</given-names></name></person-group><year>2010</year><article-title>Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC</article-title><source>Cancer Cell</source><volume>17</volume><fpage>77</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2009.11.022</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vogelstein</surname><given-names>B</given-names></name><name><surname>Papadopoulos</surname><given-names>N</given-names></name><name><surname>Velculescu</surname><given-names>VE</given-names></name><name><surname>Zhou</surname><given-names>S</given-names></name><name><surname>Diaz</surname><given-names>LAJ</given-names></name><name><surname>Kinzler</surname><given-names>KW</given-names></name></person-group><year>2013</year><article-title>Cancer genome landscapes</article-title><source>Science</source><volume>339</volume><fpage>1546</fpage><lpage>1558</lpage><pub-id pub-id-type="doi">10.1126/science.1235122</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>William</surname><given-names>WNJ</given-names></name><name><surname>Heymach</surname><given-names>JV</given-names></name><name><surname>Kim</surname><given-names>ES</given-names></name><name><surname>Lippman</surname><given-names>SM</given-names></name></person-group><year>2009</year><article-title>Molecular targets for cancer chemoprevention</article-title><source>Nature Reviews. Drug Discovery</source><volume>8</volume><fpage>213</fpage><lpage>225</lpage><pub-id pub-id-type="doi">10.1038/nrd2663</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wodarz</surname><given-names>D</given-names></name><name><surname>Komarova</surname><given-names>N</given-names></name></person-group><year>2007</year><article-title>Can loss of apoptosis protect against cancer?</article-title><source>Trends in Genetics</source><volume>23</volume><fpage>232</fpage><lpage>237</lpage><pub-id pub-id-type="doi">10.1016/j.tig.2007.03.005</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Lippman</surname><given-names>SM</given-names></name></person-group><year>2011</year><article-title>An intermittent approach for cancer chemoprevention</article-title><source>Nature Reviews. Cancer</source><volume>11</volume><fpage>879</fpage><lpage>885</lpage><pub-id pub-id-type="doi">10.1038/nrc3167</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yap</surname><given-names>TA</given-names></name></person-group><year>2015</year><article-title>Challenges in combining novel molecularly targeted agents in cancer medicine</article-title><source>Annals of Oncology</source><volume>26</volume><fpage>9</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdu483</pub-id></element-citation></ref></ref-list><app-group><app id="app1"><title>Appendix 1</title><boxed-text><sec id="s6" sec-type="appendix"><title>Mean-field approach</title><p>We use the mean-field approach (see for example, <xref ref-type="bibr" rid="bib49">Krapivsky et al., 2010</xref>), which approximates the behaviour of a system consisting of many cells, so that the effects of stochasticity are averaged, and an intermediate state is described by a set of ordinary differential equations.</p><sec id="s6-1"><title>Master equations</title><p>We write master equations to track the probability <italic>P</italic><sub><italic>ij</italic></sub>(<italic>t</italic>) that a randomly chosen cell from a population of tumour cells is of type (<italic>i</italic>, <italic>j</italic>) at time <italic>t</italic>.</p><p>The temporal dynamics of probabilities <italic>P</italic><sub><italic>ij</italic></sub>(<italic>t</italic>), <italic>i</italic> = 0, 1, …, <italic>N</italic>, where <italic>N</italic> is the maximal number of additionally acquired drivers and <italic>j</italic> = 0, 1, are described by:<disp-formula id="equ2"><mml:math id="m2"><mml:mrow><mml:mfrac><mml:mrow><mml:mtext>d</mml:mtext><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mtext>d</mml:mtext><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi mathvariant="double-struck">P</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi>u</mml:mi><mml:msubsup><mml:mi mathvariant="double-struck">P</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>u</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mi>v</mml:mi><mml:msubsup><mml:mi mathvariant="double-struck">P</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>v</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msubsup><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula></p><p>Here, the right-hand side is a superposition of probabilistic in- and out-flows from different mutational states to the current one (<italic>i</italic>, <italic>j</italic>). The function ℙ<sub><italic>ij</italic></sub> describes the growth of subclone (<italic>i</italic>, <italic>j</italic>) and is proportional to the probability <italic>P</italic><sub><italic>ij</italic></sub>(<italic>t</italic>), multiplied by the difference between fitness <italic>f</italic><sub><italic>ij</italic></sub> and its average value over the whole population <inline-formula><mml:math id="inf3"><mml:mrow><mml:mrow><mml:mover accent="true"><mml:mi>f</mml:mi><mml:mo>¯</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:munder><mml:mstyle displaystyle="true"><mml:mo>∑</mml:mo></mml:mstyle><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:munder><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula>. Functions <inline-formula><mml:math id="inf4"><mml:mrow><mml:msubsup><mml:mi mathvariant="double-struck">P</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>u</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="inf5"><mml:mrow><mml:msubsup><mml:mi mathvariant="double-struck">P</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>v</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula> represent the probabilistic flows of mutations. For <inline-formula><mml:math id="inf6"><mml:mrow><mml:msubsup><mml:mi mathvariant="double-struck">P</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>u</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula>, a driver is added from class (<italic>i</italic> − 1, <italic>j</italic>) to (<italic>i</italic>, <italic>j</italic>) in proportion to the probability <inline-formula><mml:math id="inf7"><mml:mrow><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>−</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula>, the probability of cell birth <italic>b</italic><sub><italic>i</italic>−1,<italic>j</italic></sub>, and the probability of a zero locus being chosen from <italic>N</italic> total loci consisting of (<italic>N</italic> − (<italic>i</italic> − 1)) other zero loci. A similar approach is used to define the outflow term for the probability from class (<italic>i</italic>, <italic>j</italic>) to (<italic>i</italic> + 1, <italic>j</italic>). The second term <inline-formula><mml:math id="inf8"><mml:mrow><mml:msubsup><mml:mi mathvariant="double-struck">P</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>v</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula> is the probability of mutating to therapeutic resistance (<italic>i</italic>, <italic>j</italic> = 0) to (<italic>i</italic>, <italic>j</italic> = 1) and is proportional to <italic>P</italic><sub><italic>i</italic>0</sub>(<italic>t</italic>) and birth rate <italic>b</italic><sub><italic>i</italic>0</sub>. Finally, all terms are summed, taking into account the initial conditions: <italic>P</italic><sub>00</sub>(0) = 1 − <italic>κ</italic>, <italic>P</italic><sub>01</sub>(0) = <italic>κ</italic>, and <italic>P</italic><sub><italic>ij</italic></sub> = 0 for any other <italic>i</italic> or <italic>j</italic>.</p><p>The above elements lead to the following system of ordinary differential equations (ODEs):<disp-formula id="equ3"><label>(1)</label><mml:math id="m3"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:mrow><mml:mover accent="true"><mml:mi>f</mml:mi><mml:mo>¯</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mi>u</mml:mi><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mfrac><mml:mrow><mml:mi>i</mml:mi><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>N</mml:mi></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mfrac><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>−</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mn>2</mml:mn></mml:mfrac><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>−</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>−</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mfrac><mml:mi>i</mml:mi><mml:mi>N</mml:mi></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mfrac><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mn>2</mml:mn></mml:mfrac><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mo>−</mml:mo><mml:mi>v</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mn>2</mml:mn><mml:mi>j</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mfrac><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mn>2</mml:mn></mml:mfrac><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula>where some probabilities <italic>P</italic><sub><italic>ij</italic></sub>(<italic>t</italic>) could, theoretically, take on negative values, for example, <italic>P</italic><sub>−1,<italic>j</italic></sub>(<italic>t</italic>), when <italic>i</italic> = 0, in which case, they are set to zero.</p><p>A simple transformation,<disp-formula id="equ4"><mml:math id="m4"><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mn>0</mml:mn><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mn>0</mml:mn><mml:mo>)</mml:mo></mml:mrow><mml:mo>,</mml:mo><mml:mo> </mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mi>exp</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:munderover><mml:mstyle displaystyle="true"><mml:mo>∫</mml:mo></mml:mstyle><mml:mn>0</mml:mn><mml:mi>t</mml:mi></mml:munderover><mml:mrow><mml:mover accent="true"><mml:mi>f</mml:mi><mml:mo>¯</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>r</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mtext>d</mml:mtext><mml:mi>r</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula>allows omitting the term <inline-formula><mml:math id="inf9"><mml:mrow><mml:mrow><mml:mover accent="true"><mml:mi>f</mml:mi><mml:mo>¯</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo> </mml:mo></mml:mrow></mml:math></inline-formula> from <xref ref-type="disp-formula" rid="equ3">Equation 1</xref> and to linearize the latter with respect to the new ‘transformed’ probabilities <italic>p</italic><sub><italic>ij</italic></sub>(<italic>t</italic>). This gives:<disp-formula id="equ5"><label>(2)</label><mml:math id="m5"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mi>u</mml:mi><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mfrac><mml:mrow><mml:mi>i</mml:mi><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>N</mml:mi></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mfrac><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>−</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mn>2</mml:mn></mml:mfrac><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>−</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>−</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mfrac><mml:mi>i</mml:mi><mml:mi>N</mml:mi></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mfrac><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mn>2</mml:mn></mml:mfrac><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mi>v</mml:mi><mml:mfrac><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mn>2</mml:mn></mml:mfrac><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula>where, for convenience, we write (<italic>jp</italic><sub><italic>i</italic>,<italic>j</italic>−1</sub>(<italic>t</italic>) + (<italic>j</italic> − 1)<italic>p</italic><sub><italic>ij</italic></sub>(<italic>t</italic>)) instead of (1 − 2<italic>j</italic>)<italic>p</italic><sub><italic>i</italic>0</sub>(<italic>t</italic>).</p></sec><sec id="s6-2"><title>Probability generating function approach</title><p>With <xref ref-type="disp-formula" rid="equ5">Equation 2</xref> we apply the probability generating function (p.g.f.) method (<xref ref-type="bibr" rid="bib27">Gardiner, 2004</xref>; <xref ref-type="bibr" rid="bib4">Assaf, 2010</xref>) to transform the system of (2<italic>N</italic> + 1) ODEs to a Hamilton–Jacobi (HJ) equation, that is, a first order partial differential equation.</p><p>We define the p.g.f. as the polynomial over all modified probabilities <italic>p</italic><sub><italic>ij</italic></sub>(<italic>t</italic>) of the form:<disp-formula id="equ6"><label>(3)</label><mml:math id="m6"><mml:mrow><mml:mi>G</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>ξ</mml:mi><mml:mo>,</mml:mo><mml:mi>η</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:munderover><mml:mstyle displaystyle="true"><mml:mo>∑</mml:mo></mml:mstyle><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow><mml:mi>N</mml:mi></mml:munderover><mml:munderover><mml:mstyle displaystyle="true"><mml:mo>∑</mml:mo></mml:mstyle><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow><mml:mn>1</mml:mn></mml:munderover><mml:msup><mml:mi>ξ</mml:mi><mml:mi>i</mml:mi></mml:msup><mml:msup><mml:mi>η</mml:mi><mml:mi>j</mml:mi></mml:msup><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula>where <italic>ξ</italic> and <italic>η</italic> are the variables that can be viewed as the momentum of an auxiliary Hamiltonian system governing the leading-order stochastic dynamics of the system (<xref ref-type="bibr" rid="bib19">Elgart and Kamenev, 2004</xref>). Notice that the function <italic>G</italic>(<italic>ξ</italic>, <italic>η</italic>, <italic>t</italic>) is linear with respect to <italic>η</italic>.</p><p>Suppose that the function <italic>G</italic>(<italic>ξ</italic>, <italic>η</italic>, <italic>t</italic>) is defined. One can then obtain all characteristics of the stochastic process, such as the average tumour size <italic>n</italic>(<italic>t</italic>) and the average frequency <italic>n</italic><sub><italic>res</italic></sub>(<italic>t</italic>)/<italic>n</italic>(<italic>t</italic>) of resistant cells within a tumour. The former quantity is:<disp-formula id="equ7"><mml:math id="m7"><mml:mrow><mml:mfrac><mml:mrow><mml:mtext>d</mml:mtext><mml:mi>n</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mtext>d</mml:mtext><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mi>n</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mover accent="true"><mml:mi>f</mml:mi><mml:mo>¯</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula></p><p>Using the normalization condition for the probability: <inline-formula><mml:math id="inf10"><mml:mrow><mml:munder><mml:mstyle displaystyle="true"><mml:mo>∑</mml:mo></mml:mstyle><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:munder><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula>, we obtain:<disp-formula id="equ8"><mml:math id="m8"><mml:mrow><mml:mi>G</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>ξ</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>η</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mi>exp</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:munderover><mml:mstyle displaystyle="true"><mml:mo>∫</mml:mo></mml:mstyle><mml:mn>0</mml:mn><mml:mi>t</mml:mi></mml:munderover><mml:mrow><mml:mrow><mml:mover accent="true"><mml:mi>f</mml:mi><mml:mo>¯</mml:mo></mml:mover></mml:mrow></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>r</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mtext>d</mml:mtext><mml:mi>r</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula></p><p>and then:<disp-formula id="equ9"><label>(4)</label><mml:math id="m9"><mml:mrow><mml:mi>n</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:msub><mml:mi>M</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo> </mml:mo><mml:mi>exp</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:munderover><mml:mstyle displaystyle="true"><mml:mo>∫</mml:mo></mml:mstyle><mml:mn>0</mml:mn><mml:mi>t</mml:mi></mml:munderover><mml:mrow><mml:mover accent="true"><mml:mi>f</mml:mi><mml:mo>¯</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>r</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mtext>d</mml:mtext><mml:mi>r</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:msub><mml:mi>M</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mi>G</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>ξ</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>η</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula>where the initial tumour size <italic>n</italic>(0) = <italic>M</italic><sub>0</sub> is sufficiently large. The frequency of resistant cells is defined as follows:<disp-formula id="equ10"><label>(5)</label><mml:math id="m10"><mml:mrow><mml:mfrac><mml:mrow><mml:msub><mml:mi>n</mml:mi><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mi>n</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:munderover><mml:mstyle displaystyle="true"><mml:mo>∑</mml:mo></mml:mstyle><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow><mml:mi>N</mml:mi></mml:munderover><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:munderover><mml:mstyle displaystyle="true"><mml:mo>∑</mml:mo></mml:mstyle><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow><mml:mi>N</mml:mi></mml:munderover><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mi>exp</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mo>−</mml:mo><mml:munderover><mml:mstyle displaystyle="true"><mml:mo>∫</mml:mo></mml:mstyle><mml:mn>0</mml:mn><mml:mi>t</mml:mi></mml:munderover><mml:mrow><mml:mover accent="true"><mml:mi>f</mml:mi><mml:mo>¯</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>r</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mtext>d</mml:mtext><mml:mi>r</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mo> </mml:mo><mml:msub><mml:mrow><mml:mrow><mml:mrow><mml:mfrac><mml:mrow><mml:mo>∂</mml:mo><mml:mi>G</mml:mi><mml:mo>/</mml:mo><mml:mo>∂</mml:mo><mml:mi>η</mml:mi></mml:mrow><mml:mrow><mml:mi>G</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>ξ</mml:mi><mml:mo>,</mml:mo><mml:mi>η</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac></mml:mrow><mml:mo>|</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mtable><mml:mtr><mml:mtd><mml:mrow><mml:mi>ξ</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:mi>η</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:msub><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula></p><p>Initial conditions yield <italic>p</italic><sub>00</sub>(0) = 1 − <italic>κ</italic>, <italic>p</italic><sub>01</sub>(0) = <italic>κ</italic>, and <italic>p</italic><sub><italic>ij</italic></sub>(0) = 0 for any other <italic>i</italic> and <italic>j</italic>, so that <italic>G</italic>(<italic>ξ</italic>, <italic>η</italic>, <italic>t</italic> = 0) = 1 − <italic>κ</italic> + <italic>κη</italic>.</p><p>To obtain the HJ equation related to the p.g.f. <italic>G</italic>(<italic>ξ</italic>, <italic>η</italic>, <italic>t</italic>), we multiply <xref ref-type="disp-formula" rid="equ5">Equation 2</xref> with <italic>ξ</italic><sup><italic>i</italic></sup><italic>η</italic><sup><italic>j</italic></sup> and sum up all equations for <italic>i</italic> = 0, 1,…,<italic>N</italic> and <italic>j</italic> = 0, 1. After some algebra, we obtain:<disp-formula id="equ11"><label>(6)</label><mml:math id="m11"><mml:mrow><mml:mfrac><mml:mrow><mml:mo>∂</mml:mo><mml:mi>G</mml:mi></mml:mrow><mml:mrow><mml:mo>∂</mml:mo><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mi>s</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>ξ</mml:mi><mml:mfrac><mml:mo>∂</mml:mo><mml:mrow><mml:mo>∂</mml:mo><mml:mi>ξ</mml:mi></mml:mrow></mml:mfrac><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>−</mml:mo><mml:mi>σ</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>η</mml:mi><mml:mfrac><mml:mo>∂</mml:mo><mml:mrow><mml:mo>∂</mml:mo><mml:mi>η</mml:mi></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>−</mml:mo><mml:mi>c</mml:mi><mml:mi>η</mml:mi><mml:mfrac><mml:mo>∂</mml:mo><mml:mrow><mml:mo>∂</mml:mo><mml:mi>η</mml:mi></mml:mrow></mml:mfrac><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mi>u</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>ξ</mml:mi><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mn>2</mml:mn></mml:mfrac><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mfrac><mml:mi>ξ</mml:mi><mml:mi>N</mml:mi></mml:mfrac><mml:mfrac><mml:mo>∂</mml:mo><mml:mrow><mml:mo>∂</mml:mo><mml:mi>ξ</mml:mi></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mi>v</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>η</mml:mi><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mn>2</mml:mn></mml:mfrac><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>η</mml:mi><mml:mfrac><mml:mo>∂</mml:mo><mml:mrow><mml:mo>∂</mml:mo><mml:mi>η</mml:mi></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mi>G</mml:mi><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula>where only terms of order greater than or equal to <italic>u</italic>, <italic>v</italic> are retained, meaning that terms composed of the products <italic>s</italic>, <italic>c</italic>, and <italic>u</italic>, <italic>v</italic> are omitted.</p><p><xref ref-type="disp-formula" rid="equ11">Equation 6</xref> is solved by the method of characteristics such that the HJ equation is transformed into a system of ordinary differential equations (i.e., the system of characteristics, see e.g., <xref ref-type="bibr" rid="bib55">Melikyan, 1998</xref>).</p></sec><sec id="s6-3"><title>Time-varied treatment schedule</title><p>We find the characteristics for the variables <italic>ξ</italic> and <italic>η</italic> using (<xref ref-type="disp-formula" rid="equ11">Equation 6</xref>):<disp-formula id="equ12"><label>(7)</label><mml:math id="m12"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mi>ξ</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:mi>s</mml:mi><mml:mi>ξ</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mi>u</mml:mi><mml:mi>ξ</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>ξ</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mi>N</mml:mi></mml:mrow></mml:mfrac><mml:mo>,</mml:mo><mml:mo> </mml:mo><mml:mfrac><mml:mrow><mml:mtext>d</mml:mtext><mml:mi>η</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mtext>d</mml:mtext><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>c</mml:mi><mml:mo>−</mml:mo><mml:mi>σ</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>η</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mi>v</mml:mi><mml:mi>η</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>η</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mn>2</mml:mn></mml:mfrac><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula>where <italic>σ</italic>(<italic>t</italic>) is a given function of time.</p><p>The p.g.f. <italic>G</italic>(<italic>ξ</italic>, <italic>η</italic>, <italic>t</italic>) changes along the characteristic <xref ref-type="disp-formula" rid="equ12">Equation 7</xref> according to the following ODE:<disp-formula id="equ13"><label>(8)</label><mml:math id="m13"><mml:mrow><mml:mfrac><mml:mrow><mml:mtext>d</mml:mtext><mml:mi>G</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mtext>d</mml:mtext><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>s</mml:mi><mml:mo>−</mml:mo><mml:mi>σ</mml:mi><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mi>u</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>ξ</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mn>2</mml:mn></mml:mfrac><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mi>v</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>η</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mn>2</mml:mn></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>G</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula>which is straightforward to integrate. Indeed, if we use <xref ref-type="disp-formula" rid="equ12">Equation 7</xref>, this yields dln<italic>G</italic> = (<italic>s</italic>(<italic>N</italic> + 1) − <italic>c</italic>)d<italic>t</italic> + <italic>N</italic>dln<italic>ξ</italic> + dln<italic>η</italic>. Thus,<disp-formula id="equ14"><label>(9)</label><mml:math id="m14"><mml:mrow><mml:mi>G</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>ξ</mml:mi><mml:mo>,</mml:mo><mml:mi>η</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>exp</mml:mi><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mo>−</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>s</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>N</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>−</mml:mo><mml:mi>c</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>t</mml:mi><mml:mo>−</mml:mo><mml:mi>N</mml:mi><mml:mo> </mml:mo><mml:mi>ln</mml:mi><mml:mo> </mml:mo><mml:mi>ξ</mml:mi><mml:mo>−</mml:mo><mml:mi>ln</mml:mi><mml:mo> </mml:mo><mml:mi>η</mml:mi></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mi>c</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mi>s</mml:mi><mml:mi>t</mml:mi><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula></p><p>Recall that the quantity on the left hand side remains constant only along the characteristic curve (<xref ref-type="disp-formula" rid="equ12">Equation 7</xref>).</p><p>To obtain <italic>G</italic>(<italic>ξ</italic> = 1, <italic>η</italic> = 1, <italic>t</italic>), we need to solve <xref ref-type="disp-formula" rid="equ12">Equation 7</xref> subject to <italic>ξ</italic>(<italic>t</italic>) = <italic>η</italic>(<italic>t</italic>) = 1 and find <italic>ξ</italic>(0) and <italic>η</italic>(0). Then, given the initial condition <italic>G</italic>(<italic>ξ</italic>(0),<italic>η</italic>(0),0) = 1 − <italic>κ</italic> + <italic>κη</italic>(0), <italic>κ</italic> is a level of resistance within a tumour (<italic>κ</italic> ∈ [0,1]), we can define <italic>G</italic>(<italic>ξ</italic>, <italic>η</italic>, <italic>t</italic>) using <xref ref-type="disp-formula" rid="equ14">Equation 9</xref>.</p><p>Finally, we use <xref ref-type="disp-formula" rid="equ9">Equation 4</xref> to derive the dynamics of <italic>n</italic>(<italic>t</italic>). To obtain the mean frequency of resistant cells within a tumour, we first write ∂<italic>G</italic>/∂<italic>η</italic>, using <xref ref-type="disp-formula" rid="equ14">Equation 9</xref> with the right hand side implicitly dependent on <italic>η</italic> and then substitute it into <xref ref-type="disp-formula" rid="equ10">Equation 5</xref>. (Note that time <italic>t</italic> is measured in cell cycles, which are assumed to be of 4 days on average. To derive all necessary equations with respect to the actual time, we need to divide <italic>t</italic> by the length of the cell-cycle and substitute it in the equations.)</p></sec><sec id="s6-4"><title>Constant treatment</title><p>We study the case for constant <italic>σ</italic>. Notice that this includes the case of no treatment (<italic>σ</italic> = 0).</p><p>First, we find the characteristics for the variables <italic>ξ</italic> and <italic>η</italic>. Namely, the solution of <xref ref-type="disp-formula" rid="equ12">Equation 7</xref> gives:<disp-formula id="equ15"><label>(10)</label><mml:math id="m15"><mml:mrow><mml:mi>ξ</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mn>0</mml:mn><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>s</mml:mi><mml:mo>+</mml:mo><mml:mi>u</mml:mi><mml:mo>/</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mn>2</mml:mn><mml:mi>N</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:mi>s</mml:mi><mml:mo>+</mml:mo><mml:mi>u</mml:mi><mml:mo>/</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mn>2</mml:mn><mml:mi>N</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mi>ξ</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:mo>−</mml:mo><mml:mfrac><mml:mi>u</mml:mi><mml:mrow><mml:mn>2</mml:mn><mml:mi>N</mml:mi></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>−</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>s</mml:mi><mml:mo>+</mml:mo><mml:mi>u</mml:mi><mml:mo>/</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mn>2</mml:mn><mml:mi>N</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mfrac><mml:mi>u</mml:mi><mml:mrow><mml:mn>2</mml:mn><mml:mi>N</mml:mi></mml:mrow></mml:mfrac></mml:mrow></mml:mfrac><mml:mo>,</mml:mo><mml:mo> </mml:mo><mml:mi>η</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mn>0</mml:mn><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>σ</mml:mi><mml:mo>−</mml:mo><mml:mi>c</mml:mi><mml:mo>+</mml:mo><mml:mi>v</mml:mi><mml:mo>/</mml:mo><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:mi>σ</mml:mi><mml:mo>−</mml:mo><mml:mi>c</mml:mi><mml:mo>+</mml:mo><mml:mi>v</mml:mi><mml:mo>/</mml:mo><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mi>η</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:mo>−</mml:mo><mml:mfrac><mml:mi>v</mml:mi><mml:mn>2</mml:mn></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>−</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>σ</mml:mi><mml:mo>−</mml:mo><mml:mi>c</mml:mi><mml:mo>+</mml:mo><mml:mi>v</mml:mi><mml:mo>/</mml:mo><mml:mn>2</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mfrac><mml:mi>v</mml:mi><mml:mn>2</mml:mn></mml:mfrac></mml:mrow></mml:mfrac><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula></p><p>The subsequent substitution of <xref ref-type="disp-formula" rid="equ15">Equation 10</xref> into <xref ref-type="disp-formula" rid="equ13">Equation 8</xref> leads to:<disp-formula id="equ16"><mml:math id="m16"><mml:mrow><mml:mi>G</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>ξ</mml:mi><mml:mo>,</mml:mo><mml:mi>η</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mi>G</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>ξ</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mn>0</mml:mn><mml:mo>)</mml:mo></mml:mrow><mml:mo>,</mml:mo><mml:mi>η</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mn>0</mml:mn><mml:mo>)</mml:mo></mml:mrow><mml:mo>,</mml:mo><mml:mn>0</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>exp</mml:mi><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>s</mml:mi><mml:mo>−</mml:mo><mml:mi>σ</mml:mi><mml:mo>−</mml:mo><mml:mfrac><mml:mrow><mml:mi>u</mml:mi><mml:mo>+</mml:mo><mml:mi>v</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>t</mml:mi><mml:mo>+</mml:mo><mml:mi>N</mml:mi><mml:mo> </mml:mo><mml:mi>ln</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mi>ξ</mml:mi><mml:mi>u</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mi>N</mml:mi></mml:mrow></mml:mfrac><mml:mfrac><mml:mrow><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>s</mml:mi><mml:mo>+</mml:mo><mml:mi>u</mml:mi><mml:mo>/</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mn>2</mml:mn><mml:mi>N</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>s</mml:mi><mml:mo>+</mml:mo><mml:mi>u</mml:mi><mml:mo>/</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mn>2</mml:mn><mml:mi>N</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:mo> </mml:mo></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mi>ln</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mi>η</mml:mi><mml:mi>v</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:mfrac><mml:mfrac><mml:mrow><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>σ</mml:mi><mml:mo>−</mml:mo><mml:mi>c</mml:mi><mml:mo>+</mml:mo><mml:mi>v</mml:mi><mml:mo>/</mml:mo><mml:mn>2</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>σ</mml:mi><mml:mo>−</mml:mo><mml:mi>c</mml:mi><mml:mo>+</mml:mo><mml:mi>v</mml:mi><mml:mo>/</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula></p><p>Taking into account <italic>u</italic>, <italic>v</italic> ≪ <italic>s</italic>, <italic>c</italic> and assuming <italic>v</italic> ≪ <italic>σ</italic> − <italic>c</italic>, we simplify further and write its approximate form:<disp-formula id="equ17"><mml:math id="m17"><mml:mrow><mml:mi>G</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>ξ</mml:mi><mml:mo>,</mml:mo><mml:mi>η</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>≅</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>κ</mml:mi><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mi>κ</mml:mi><mml:mi>η</mml:mi><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>σ</mml:mi><mml:mo>−</mml:mo><mml:mi>c</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mi>η</mml:mi><mml:mi>v</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:mfrac><mml:mfrac><mml:mrow><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>σ</mml:mi><mml:mo>−</mml:mo><mml:mi>c</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>σ</mml:mi><mml:mo>−</mml:mo><mml:mi>c</mml:mi></mml:mrow></mml:mfrac></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>exp</mml:mi><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>s</mml:mi><mml:mo>−</mml:mo><mml:mi>σ</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>t</mml:mi><mml:mo>+</mml:mo><mml:mi>N</mml:mi><mml:mo> </mml:mo><mml:mi>ln</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mi>ξ</mml:mi><mml:mi>u</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mi>N</mml:mi></mml:mrow></mml:mfrac><mml:mfrac><mml:mrow><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>s</mml:mi></mml:mfrac><mml:mo> </mml:mo></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mi>ln</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mi>η</mml:mi><mml:mi>v</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:mfrac><mml:mfrac><mml:mrow><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>σ</mml:mi><mml:mo>−</mml:mo><mml:mi>c</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>σ</mml:mi><mml:mo>−</mml:mo><mml:mi>c</mml:mi></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula></p><p>which can be also written in the form:<disp-formula id="equ18"><label>(11)</label><mml:math id="m18"><mml:mrow><mml:mi>G</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>ξ</mml:mi><mml:mo>,</mml:mo><mml:mi>η</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>≅</mml:mo><mml:mo> </mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>κ</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mi>η</mml:mi><mml:mi>v</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:mfrac><mml:mfrac><mml:mrow><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>σ</mml:mi><mml:mo>−</mml:mo><mml:mi>c</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>σ</mml:mi><mml:mo>−</mml:mo><mml:mi>c</mml:mi></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mi>κ</mml:mi><mml:mi>η</mml:mi><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>σ</mml:mi><mml:mo>−</mml:mo><mml:mi>c</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>exp</mml:mi><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>s</mml:mi><mml:mo>−</mml:mo><mml:mi>σ</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>t</mml:mi><mml:mo>+</mml:mo><mml:mi>N</mml:mi><mml:mo> </mml:mo><mml:mi>ln</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mi>ξ</mml:mi><mml:mi>u</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mi>N</mml:mi></mml:mrow></mml:mfrac><mml:mfrac><mml:mrow><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>s</mml:mi></mml:mfrac><mml:mo> </mml:mo></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula></p><p>As expected <xref ref-type="disp-formula" rid="equ18">Equation 11</xref> is linear with respect to <italic>η</italic>.</p><p>Thus, we derive an analytical expression for the dynamics <italic>n</italic>(<italic>t</italic>). Namely, we use <xref ref-type="disp-formula" rid="equ9">Equations 4</xref> and <xref ref-type="disp-formula" rid="equ18">11</xref> and substitute <italic>ξ</italic> = <italic>η</italic> = 1, to obtain:<disp-formula id="equ19"><label>(12)</label><mml:math id="m19"><mml:mrow><mml:mi>n</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:msub><mml:mi>M</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>κ</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mfrac><mml:mi>v</mml:mi><mml:mn>2</mml:mn></mml:mfrac><mml:mfrac><mml:mrow><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>σ</mml:mi><mml:mo>−</mml:mo><mml:mi>c</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>σ</mml:mi><mml:mo>−</mml:mo><mml:mi>c</mml:mi></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mi>κ</mml:mi><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>σ</mml:mi><mml:mo>−</mml:mo><mml:mi>c</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>exp</mml:mi><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>s</mml:mi><mml:mo>−</mml:mo><mml:mi>σ</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>t</mml:mi><mml:mo>+</mml:mo><mml:mi>N</mml:mi><mml:mo> </mml:mo><mml:mi>ln</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mfrac><mml:mi>u</mml:mi><mml:mrow><mml:mn>2</mml:mn><mml:mi>N</mml:mi></mml:mrow></mml:mfrac><mml:mfrac><mml:mrow><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>s</mml:mi></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula></p><p><xref ref-type="disp-formula" rid="equ19">Equation 12</xref> is simplified for two limiting cases. In the early stages of tumour growth, the value <italic>n</italic>(<italic>t</italic>) changes according to a hyper-exponential law:<disp-formula id="equ20"><mml:math id="m20"><mml:mrow><mml:mi>n</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>≅</mml:mo><mml:msub><mml:mi>M</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>κ</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mfrac><mml:mi>v</mml:mi><mml:mn>2</mml:mn></mml:mfrac><mml:mfrac><mml:mrow><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>σ</mml:mi><mml:mo>−</mml:mo><mml:mi>c</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>σ</mml:mi><mml:mo>−</mml:mo><mml:mi>c</mml:mi></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mi>κ</mml:mi><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>σ</mml:mi><mml:mo>−</mml:mo><mml:mi>c</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>exp</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>s</mml:mi><mml:mo>−</mml:mo><mml:mi>σ</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>t</mml:mi><mml:mo>+</mml:mo><mml:mfrac><mml:mi>u</mml:mi><mml:mn>2</mml:mn></mml:mfrac><mml:mfrac><mml:mrow><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>s</mml:mi></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula></p><p>while at later stages, the most aggressive subclone persists, being sensitive if <italic>σ</italic> &lt; <italic>c</italic> (<italic>n</italic>(<italic>t</italic>) ∝ <italic>e</italic><sup><italic>s</italic>(<italic>N</italic>+1)<italic>t</italic></sup>) and resistant otherwise (<italic>n</italic>(<italic>t</italic>) ∝ <italic>e</italic><sup>(<italic>s</italic>(<italic>N</italic> + 1) − <italic>c</italic>)<italic>t</italic></sup>).</p><p>To compute the frequency of resistant cells within a tumour (<xref ref-type="disp-formula" rid="equ10">Equation 5</xref>), we derive ∂<italic>G</italic>/∂<italic>η</italic> using <xref ref-type="disp-formula" rid="equ18">Equation 11</xref>:<disp-formula id="equ21"><mml:math id="m21"><mml:mrow><mml:mfrac><mml:mrow><mml:mo>∂</mml:mo><mml:mi>G</mml:mi></mml:mrow><mml:mrow><mml:mo>∂</mml:mo><mml:mi>η</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mo> </mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>κ</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mfrac><mml:mi>v</mml:mi><mml:mn>2</mml:mn></mml:mfrac><mml:mfrac><mml:mrow><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>σ</mml:mi><mml:mo>−</mml:mo><mml:mi>c</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>σ</mml:mi><mml:mo>−</mml:mo><mml:mi>c</mml:mi></mml:mrow></mml:mfrac><mml:mo>+</mml:mo><mml:mi>κ</mml:mi><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>σ</mml:mi><mml:mo>−</mml:mo><mml:mi>c</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>exp</mml:mi><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>s</mml:mi><mml:mo>−</mml:mo><mml:mi>σ</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>t</mml:mi><mml:mo>+</mml:mo><mml:mi>N</mml:mi><mml:mo> </mml:mo><mml:mi>ln</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mi>ξ</mml:mi><mml:mi>u</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mi>N</mml:mi></mml:mrow></mml:mfrac><mml:mfrac><mml:mrow><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>s</mml:mi></mml:mfrac><mml:mo> </mml:mo></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula></p><p>so that:<disp-formula id="equ22"><mml:math id="m22"><mml:mrow><mml:mfrac><mml:mrow><mml:msub><mml:mi>n</mml:mi><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mi>n</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>κ</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mfrac><mml:mi>v</mml:mi><mml:mn>2</mml:mn></mml:mfrac><mml:mfrac><mml:mrow><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>σ</mml:mi><mml:mo>−</mml:mo><mml:mi>c</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>σ</mml:mi><mml:mo>−</mml:mo><mml:mi>c</mml:mi></mml:mrow></mml:mfrac><mml:mo>+</mml:mo><mml:mi>κ</mml:mi><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>σ</mml:mi><mml:mo>−</mml:mo><mml:mi>c</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msup><mml:mo> </mml:mo></mml:mrow><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>κ</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mfrac><mml:mi>v</mml:mi><mml:mn>2</mml:mn></mml:mfrac><mml:mfrac><mml:mrow><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>σ</mml:mi><mml:mo>−</mml:mo><mml:mi>c</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>σ</mml:mi><mml:mo>−</mml:mo><mml:mi>c</mml:mi></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mi>κ</mml:mi><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>σ</mml:mi><mml:mo>−</mml:mo><mml:mi>c</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:mfrac><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula></p><p><xref ref-type="fig" rid="fig7">Appendix 1—figure 1</xref> shows the excellent correspondence between numerical experiments and analytical results for <italic>σ</italic> on the order of <italic>s</italic>. <xref ref-type="fig" rid="fig8">Appendix 1—figure 2</xref> provides additional details on distribution of tumour sizes depending on the applied treatment intensity (points <italic>B</italic> and <italic>C</italic>).<fig id="fig7" position="float"><object-id pub-id-type="doi">10.7554/eLife.06266.025</object-id><label>Appendix 1—figure 1.</label><caption><title>Mean field dynamics concord with numerical simulations.</title><p>(<bold>A</bold>) Effect of treatment level and observation time on mean tumour size. (<bold>Inset</bold>) Mean frequency of resistant cells within tumours corresponding to three of the cases in <bold>A</bold>. Lines are analytically computed mean-field trajectories, while dots are numerical simulations (see <xref ref-type="app" rid="app1">Appendix 1</xref> for details). (<bold>B</bold>) Dynamics of mean and median tumour size, and percentiles around the median (shaded areas), assuming a fixed constant arresting effect of 0.15% / day. Treatments start at <italic>t</italic> = 0, and the maximal number of additionally accumulated drivers is 3. See <xref ref-type="table" rid="tbl1">Table 1</xref> for other parameter values.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.06266.025">http://dx.doi.org/10.7554/eLife.06266.025</ext-link></p></caption><graphic xlink:href="elife-06266-app1-fig1-v2.tif"/></fig><fig id="fig8" position="float"><object-id pub-id-type="doi">10.7554/eLife.06266.026</object-id><label>Appendix 1—figure 2.</label><caption><title>Trade-off between growth and resistance under different treatment regimes.</title><p>(<bold>A</bold>) Analytically derived times for a tumour to reach 10<sup>9</sup> cells (see <xref ref-type="disp-formula" rid="equ19">Equation 12</xref>). (<bold>B</bold>) and (<bold>C</bold>) Sample distributions in relative frequencies, adjusted for bins over periods of 0.5 in logarithmic scale for corresponding points <italic>B</italic> and <italic>C</italic>, shown in plot <bold>A</bold>. Dashed black line is the mean and the dashed-and-dotted line is the median. The bottom panel shows the mean number of additionally accumulated drivers for all detected tumours over the same intervals of 3 months. The colour-code indicates the level of resistance in detected tumours over these intervals. Maximal number of additionally accumulated drivers is 5. Parameters otherwise as in <xref ref-type="table" rid="tbl1">Table 1</xref>.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.06266.026">http://dx.doi.org/10.7554/eLife.06266.026</ext-link></p></caption><graphic xlink:href="elife-06266-app1-fig2-v2.tif"/></fig></p></sec><sec id="s6-5"><title>Distribution of subclones within an exponentially growing tumour</title><p>The p.g.f. <italic>G</italic>(<italic>ξ, η, t</italic>) is used to derive expressions for all <italic>P</italic><sub><italic>ij</italic></sub>(<italic>t</italic>), which are the probabilities of selecting a cell of type (<italic>i</italic>, <italic>j</italic>) from a tumour at time moment <italic>t</italic>. Namely, we need to differentiate the p.g.f. with respect to <italic>ξ</italic> and <italic>η</italic>, so that:<disp-formula id="equ23"><mml:math id="m23"><mml:mrow><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:mi>i</mml:mi><mml:mo>!</mml:mo><mml:mi>G</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>ξ</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>η</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:mfrac><mml:mrow><mml:msup><mml:mo>∂</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>+</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msup><mml:mi>G</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>ξ</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>η</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mo>∂</mml:mo><mml:msup><mml:mi>ξ</mml:mi><mml:mi>i</mml:mi></mml:msup><mml:mo>∂</mml:mo><mml:msup><mml:mi>η</mml:mi><mml:mi>j</mml:mi></mml:msup></mml:mrow></mml:mfrac><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula>where <italic>i</italic> = 0, 1,… and <italic>j</italic> = 0, 1. Thus, we write:<disp-formula id="equ24"><mml:math id="m24"><mml:mrow><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mn>00</mml:mn></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>G</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mi>G</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>κ</mml:mi></mml:mrow><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>κ</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mfrac><mml:mi>v</mml:mi><mml:mn>2</mml:mn></mml:mfrac><mml:mfrac><mml:mrow><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>σ</mml:mi><mml:mo>−</mml:mo><mml:mi>c</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>σ</mml:mi><mml:mo>−</mml:mo><mml:mi>c</mml:mi></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mi>κ</mml:mi><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>σ</mml:mi><mml:mo>−</mml:mo><mml:mi>c</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:mfrac><mml:msup><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mfrac><mml:mi>u</mml:mi><mml:mrow><mml:mn>2</mml:mn><mml:mi>N</mml:mi></mml:mrow></mml:mfrac><mml:mfrac><mml:mrow><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>s</mml:mi></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mo>−</mml:mo><mml:mi>N</mml:mi></mml:mrow></mml:msup><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula><disp-formula id="equ25"><mml:math id="m25"><mml:mrow><mml:mo> </mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mn>01</mml:mn></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mo>∂</mml:mo><mml:mi>G</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>/</mml:mo><mml:mo>∂</mml:mo><mml:mi>η</mml:mi></mml:mrow><mml:mrow><mml:mi>G</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>κ</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mfrac><mml:mi>v</mml:mi><mml:mn>2</mml:mn></mml:mfrac><mml:mfrac><mml:mrow><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>σ</mml:mi><mml:mo>−</mml:mo><mml:mi>c</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>σ</mml:mi><mml:mo>−</mml:mo><mml:mi>c</mml:mi></mml:mrow></mml:mfrac><mml:mo>+</mml:mo><mml:mi>κ</mml:mi><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>σ</mml:mi><mml:mo>−</mml:mo><mml:mi>c</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>κ</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mfrac><mml:mi>v</mml:mi><mml:mn>2</mml:mn></mml:mfrac><mml:mfrac><mml:mrow><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>σ</mml:mi><mml:mo>−</mml:mo><mml:mi>c</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>σ</mml:mi><mml:mo>−</mml:mo><mml:mi>c</mml:mi></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mi>κ</mml:mi><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>σ</mml:mi><mml:mo>−</mml:mo><mml:mi>c</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:mfrac><mml:msup><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mfrac><mml:mi>u</mml:mi><mml:mrow><mml:mn>2</mml:mn><mml:mi>N</mml:mi></mml:mrow></mml:mfrac><mml:mfrac><mml:mrow><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>s</mml:mi></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mo>−</mml:mo><mml:mi>N</mml:mi></mml:mrow></mml:msup><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula>then:<disp-formula id="equ26"><mml:math id="m26"><mml:mrow><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mn>10</mml:mn></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mo>∂</mml:mo><mml:mi>G</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>/</mml:mo><mml:mo>∂</mml:mo><mml:mi>ξ</mml:mi></mml:mrow><mml:mrow><mml:mi>G</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>κ</mml:mi></mml:mrow><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>κ</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mfrac><mml:mi>v</mml:mi><mml:mn>2</mml:mn></mml:mfrac><mml:mfrac><mml:mrow><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>σ</mml:mi><mml:mo>−</mml:mo><mml:mi>c</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>σ</mml:mi><mml:mo>−</mml:mo><mml:mi>c</mml:mi></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mi>κ</mml:mi><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>σ</mml:mi><mml:mo>−</mml:mo><mml:mi>c</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:mfrac><mml:mo> </mml:mo><mml:mfrac><mml:mi>u</mml:mi><mml:mn>2</mml:mn></mml:mfrac><mml:mfrac><mml:mrow><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>s</mml:mi></mml:mfrac><mml:msup><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mfrac><mml:mi>u</mml:mi><mml:mrow><mml:mn>2</mml:mn><mml:mi>N</mml:mi></mml:mrow></mml:mfrac><mml:mfrac><mml:mrow><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>s</mml:mi></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mo>−</mml:mo><mml:mi>N</mml:mi></mml:mrow></mml:msup><mml:mo> </mml:mo><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula><disp-formula id="equ27"><mml:math id="m27"><mml:mrow><mml:mo> </mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mn>11</mml:mn></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:mi>G</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:mfrac><mml:mrow><mml:msup><mml:mo>∂</mml:mo><mml:mn>2</mml:mn></mml:msup><mml:mi>G</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mo>∂</mml:mo><mml:mi>ξ</mml:mi><mml:mo>∂</mml:mo><mml:mi>η</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mo> </mml:mo><mml:mfrac><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>κ</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mfrac><mml:mi>v</mml:mi><mml:mn>2</mml:mn></mml:mfrac><mml:mfrac><mml:mrow><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>σ</mml:mi><mml:mo>−</mml:mo><mml:mi>c</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>σ</mml:mi><mml:mo>−</mml:mo><mml:mi>c</mml:mi></mml:mrow></mml:mfrac><mml:mo>+</mml:mo><mml:mi>κ</mml:mi><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>σ</mml:mi><mml:mo>−</mml:mo><mml:mi>c</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>κ</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mfrac><mml:mi>v</mml:mi><mml:mn>2</mml:mn></mml:mfrac><mml:mfrac><mml:mrow><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>σ</mml:mi><mml:mo>−</mml:mo><mml:mi>c</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>σ</mml:mi><mml:mo>−</mml:mo><mml:mi>c</mml:mi></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mi>κ</mml:mi><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>σ</mml:mi><mml:mo>−</mml:mo><mml:mi>c</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:mfrac><mml:mfrac><mml:mi>u</mml:mi><mml:mn>2</mml:mn></mml:mfrac><mml:mfrac><mml:mrow><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>s</mml:mi></mml:mfrac><mml:msup><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mfrac><mml:mi>u</mml:mi><mml:mrow><mml:mn>2</mml:mn><mml:mi>N</mml:mi></mml:mrow></mml:mfrac><mml:mfrac><mml:mrow><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>s</mml:mi></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mo>−</mml:mo><mml:mi>N</mml:mi></mml:mrow></mml:msup><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula></p><p>The general formula is written as follows:<disp-formula id="equ28"><mml:math id="m28"><mml:mrow><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:mi>i</mml:mi><mml:mo>!</mml:mo><mml:mi>G</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:mfrac><mml:mrow><mml:msup><mml:mo>∂</mml:mo><mml:mi>i</mml:mi></mml:msup><mml:mi>G</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mo>∂</mml:mo><mml:msup><mml:mi>ξ</mml:mi><mml:mi>i</mml:mi></mml:msup></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>κ</mml:mi></mml:mrow><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>κ</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mfrac><mml:mi>v</mml:mi><mml:mn>2</mml:mn></mml:mfrac><mml:mfrac><mml:mrow><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>σ</mml:mi><mml:mo>−</mml:mo><mml:mi>c</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>σ</mml:mi><mml:mo>−</mml:mo><mml:mi>c</mml:mi></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mi>κ</mml:mi><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>σ</mml:mi><mml:mo>−</mml:mo><mml:mi>c</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:mfrac><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>∗</mml:mo></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo> </mml:mo><mml:mo>,</mml:mo><mml:mo> </mml:mo></mml:mrow></mml:math></disp-formula><disp-formula id="equ29"><mml:math id="m29"><mml:mrow><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:mi>i</mml:mi><mml:mo>!</mml:mo><mml:mi>G</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:mfrac><mml:mrow><mml:msup><mml:mo>∂</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup><mml:mi>G</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mo>∂</mml:mo><mml:msup><mml:mi>ξ</mml:mi><mml:mi>i</mml:mi></mml:msup><mml:mo>∂</mml:mo><mml:mi>η</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mo> </mml:mo><mml:mfrac><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>κ</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mfrac><mml:mi>v</mml:mi><mml:mn>2</mml:mn></mml:mfrac><mml:mfrac><mml:mrow><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>σ</mml:mi><mml:mo>−</mml:mo><mml:mi>c</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>σ</mml:mi><mml:mo>−</mml:mo><mml:mi>c</mml:mi></mml:mrow></mml:mfrac><mml:mo>+</mml:mo><mml:mi>κ</mml:mi><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>σ</mml:mi><mml:mo>−</mml:mo><mml:mi>c</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>κ</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mfrac><mml:mi>v</mml:mi><mml:mn>2</mml:mn></mml:mfrac><mml:mfrac><mml:mrow><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>σ</mml:mi><mml:mo>−</mml:mo><mml:mi>c</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>σ</mml:mi><mml:mo>−</mml:mo><mml:mi>c</mml:mi></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mi>κ</mml:mi><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>σ</mml:mi><mml:mo>−</mml:mo><mml:mi>c</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:mfrac><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>∗</mml:mo></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula>where <italic>i</italic> = 0, 1, …<italic>N</italic>, and the function:<disp-formula id="equ30"><mml:math id="m30"><mml:mrow><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>∗</mml:mo></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mtable><mml:mtr><mml:mtd><mml:mi>N</mml:mi></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mi>i</mml:mi></mml:mtd></mml:mtr></mml:mtable></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msup><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mfrac><mml:mi>u</mml:mi><mml:mrow><mml:mn>2</mml:mn><mml:mi>N</mml:mi></mml:mrow></mml:mfrac><mml:mfrac><mml:mrow><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>s</mml:mi></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mi>i</mml:mi></mml:msup><mml:msup><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mfrac><mml:mi>u</mml:mi><mml:mrow><mml:mn>2</mml:mn><mml:mi>N</mml:mi></mml:mrow></mml:mfrac><mml:mfrac><mml:mrow><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>s</mml:mi></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mo>−</mml:mo><mml:mi>N</mml:mi></mml:mrow></mml:msup><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula>defines the probability to pick a cell with <italic>i</italic> drivers independently of resistant status, <inline-formula><mml:math id="inf11"><mml:mrow><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>∗</mml:mo></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>≜</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula>, where <inline-formula><mml:math id="inf12"><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mtable><mml:mtr><mml:mtd><mml:mi>N</mml:mi></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mi>i</mml:mi></mml:mtd></mml:mtr></mml:mtable></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> denotes a binomial coefficient, equal <inline-formula><mml:math id="inf13"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>N</mml:mi><mml:mo>!</mml:mo></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mo>!</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>N</mml:mi><mml:mo>−</mml:mo><mml:mi>i</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>!</mml:mo></mml:mrow></mml:mfrac></mml:mrow></mml:math></inline-formula>.</p><p>The distribution <italic>P</italic><sub><italic>i</italic>∗</sub>(<italic>t</italic>) for a particular case of <italic>N</italic> = 6 is shown in <xref ref-type="fig" rid="fig9">Appendix 1—figure 3</xref>.<fig id="fig9" position="float"><object-id pub-id-type="doi">10.7554/eLife.06266.027</object-id><label>Appendix 1—figure 3.</label><caption><title>Maximal tumour heterogeneity in terms of driver subclones occurs at intermediate times after initial lesion.</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.06266.027">http://dx.doi.org/10.7554/eLife.06266.027</ext-link></p></caption><graphic xlink:href="elife-06266-app1-fig3-v2.tif"/></fig></p><p>We now derive the mean time period when a given subclone with <italic>i</italic> additionally accumulated drivers dominates within a tumour.</p><p>Defining the time moments <italic>t</italic> = <italic>t</italic><sub><italic>i</italic></sub> for which <italic>P</italic><sub><italic>i</italic>−1,∗</sub>(<italic>t</italic><sub><italic>i</italic></sub>) = <italic>P</italic><sub><italic>i</italic>∗</sub>(<italic>t</italic><sub><italic>i</italic></sub>) (<italic>i</italic> = 0, 1, 2,…,<italic>N</italic>) gives:<disp-formula id="equ31"><mml:math id="m31"><mml:mrow><mml:msub><mml:mi>t</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mi>s</mml:mi></mml:mfrac><mml:mi>ln</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mn>2</mml:mn><mml:mi>s</mml:mi><mml:mi>N</mml:mi><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi>u</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>N</mml:mi><mml:mo>−</mml:mo><mml:mi>i</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>≈</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mi>s</mml:mi></mml:mfrac><mml:mi>ln</mml:mi><mml:mfrac><mml:mrow><mml:mn>2</mml:mn><mml:mi>s</mml:mi><mml:mi>N</mml:mi><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi>u</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>N</mml:mi><mml:mo>−</mml:mo><mml:mi>i</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula>where we assume <italic>u</italic> ≪ <italic>s</italic>.</p><p>The time period when the subclone with <italic>i</italic> drivers prevails in a cell population is defined by the following expression:<disp-formula id="equ32"><mml:math id="m32"><mml:mrow><mml:mtext>Δ</mml:mtext><mml:msub><mml:mi>t</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mi>s</mml:mi></mml:mfrac><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mi>ln</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mn>2</mml:mn><mml:mi>s</mml:mi><mml:mi>N</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mi>u</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>N</mml:mi><mml:mo>−</mml:mo><mml:mi>i</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>−</mml:mo><mml:mi>ln</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mn>2</mml:mn><mml:mi>s</mml:mi><mml:mi>N</mml:mi><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi>u</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>N</mml:mi><mml:mo>−</mml:mo><mml:mi>i</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mo>≈</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mi>s</mml:mi></mml:mfrac><mml:mi>ln</mml:mi><mml:mfrac><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>N</mml:mi><mml:mo>−</mml:mo><mml:mi>i</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>N</mml:mi><mml:mo>−</mml:mo><mml:mi>i</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:mfrac><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula>where <italic>i</italic> ≠ 0. For <italic>i</italic> = 0, we have:<disp-formula id="equ33"><mml:math id="m33"><mml:mrow><mml:mtext>Δ</mml:mtext><mml:msub><mml:mi>t</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mi>s</mml:mi></mml:mfrac><mml:mi>ln</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mn>2</mml:mn><mml:mi>s</mml:mi></mml:mrow><mml:mi>u</mml:mi></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>≈</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mi>s</mml:mi></mml:mfrac><mml:mi>ln</mml:mi><mml:mfrac><mml:mrow><mml:mn>2</mml:mn><mml:mi>s</mml:mi></mml:mrow><mml:mi>u</mml:mi></mml:mfrac><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula></p><p>The latter formula has been previously reported (see Equation S7 in reference <xref ref-type="bibr" rid="bib11">Bozic et al., 2010</xref>).</p></sec></sec><sec id="s7" sec-type="appendix"><title>Varying mutation rate and initial tumour size</title><p>To understand better how the inflection points emerge around <italic>σ</italic> = <italic>qs</italic> (<italic>q</italic> = 1, 2, 3,…), we first consider a much simpler case than the main text. Suppose that no additional driver mutation is acquired during tumourigenesis, <italic>u</italic> = 0. Any treatment regime of constant intensity that lowers the selective advantage (<italic>σ</italic> &lt; <italic>s</italic>) only slows tumour growth. In such cases, the median detection time increases with <italic>σ</italic> (see <xref ref-type="fig" rid="fig6">Figure 6</xref>). Assuming that resistance is not obtained, the median time to detection approaches a vertical asymptote at <italic>σ</italic> = <italic>s</italic>, whereas the tumour is always eradicated for <italic>σ</italic> &gt; <italic>s</italic>. If <italic>v</italic> &gt; 0, then the tumour relapses following the appearance of the resistance mutation, and the median detection time approaches the horizontal asymptote for <italic>σ</italic> ≫ <italic>s</italic>. Thus, the final result for the median detection time will be a line with an inflection point near σ = <italic>s</italic>, consisting of two effects: higher treatment levels resulting in the control of sensitive clones with ever higher numbers of drivers (blue colouring), and the lack of control of costly resistant clones (red colouring) (<xref ref-type="fig" rid="fig6">Figure 6</xref>).</p><p>In the general case (<italic>u</italic> &gt; 0, <italic>v</italic> &gt; 0), the median follows from the different elements cited above, consisting of several possible branches (e.g., <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1D</xref>) or none, where the latter case depends on the relation between the mutation rate <italic>u</italic> and the initial cell number <italic>M</italic><sub>0</sub> (e.g., for <italic>M</italic><sub>0</sub> = 10<sup>7</sup> see <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>).</p><p><xref ref-type="fig" rid="fig10">Appendix 1—figure 4</xref> shows an example. Panel A shows a case when <italic>u</italic> is varied and <italic>M</italic><sub>0</sub> remains fixed. We identify the key parameter for the appearance of the inflection points as <italic>M</italic><sub>0</sub><italic>u</italic>. It defines the emergence probability of the next subclone with one additional driver. Hence, the inflection points are more apparent for smaller values of <italic>M</italic><sub>0</sub><italic>u</italic> and vanish for larger values of <italic>M</italic><sub>0</sub><italic>u</italic>. This same tendency can be seen in <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>, where <italic>M</italic><sub>0</sub> is varied and <italic>u</italic> is fixed. Panels B, C, and D provide more details on the interplay between <italic>M</italic><sub>0</sub><italic>u</italic> and the inflection points.<fig id="fig10" position="float"><object-id pub-id-type="doi">10.7554/eLife.06266.028</object-id><label>Appendix 1—figure 4.</label><caption><title>Sensitivity analysis of (<bold>A</bold>) the mutation rate to acquire drivers and (<bold>B</bold>–<bold>D</bold>) initial tumour size.</title><p>Thick lines indicate the median and shaded areas with dashed boundaries the 90% confidence intervals of detection times. (<bold>A</bold>) Initial tumour size is fixed at 10<sup>6</sup> cells and mutation rate is varied. (<bold>B</bold>–<bold>D</bold>) Initial tumour size is varied and mutation rate is fixed at (<bold>B</bold>) 10<sup>−6</sup>, (<bold>C</bold>) 3.4 × 10<sup>−5</sup>, (<bold>D</bold>) 10<sup>−3</sup>. The colour code for points indicates the average level of resistance within tumours (see the inset in <bold>B</bold>). Parameter values as in <xref ref-type="table" rid="tbl1">Table 1</xref> except those being varied.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.06266.028">http://dx.doi.org/10.7554/eLife.06266.028</ext-link></p></caption><graphic xlink:href="elife-06266-app1-fig4-v2.tif"/></fig></p></sec><sec id="s8" sec-type="appendix"><title>A simple form of drug addiction for resistant cell-lines</title><p>To explore the possible effects of drug addiction on tumour growth, we propose a simple modification of the fitness function. Suppose the cost of resistance C is given by the relation:<disp-formula id="equ34"><mml:math id="m34"><mml:mrow><mml:mtext>C</mml:mtext><mml:mo>=</mml:mo><mml:mi>c</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mfrac><mml:mrow><mml:mn>2</mml:mn><mml:mi>σ</mml:mi></mml:mrow><mml:mi>s</mml:mi></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula></p><p>It equals <italic>c</italic> as before when no treatment is applied (<italic>σ</italic> = 0), while drug addiction increases with larger <italic>σ</italic>. The cost equals zero at <italic>σ</italic> = 2<italic>s</italic> and becomes negative for <italic>σ</italic> &gt; 2<italic>s</italic>, implying that further drug administration has a beneficial effect on proliferation of resistant cells. Fischer and colleagues (<xref ref-type="bibr" rid="bib22">Fischer et al., 2015</xref>) argue that under drug addiction, a metronomic treatment strategy is more beneficial than a constantly applied treatment. The metronomic strategy imposes a simple rule: treatment is only applied when the number of non-resistant cells exceeds the number of resistant cells.</p><p>We compare the originally studied model, where the resistant cells exhibit no drug addiction, with a modified case of resistant cell drug addiction. In the latter, we consider two different treatment regimes: a constantly administrated drug application and metronomic therapy. As an example, <xref ref-type="fig" rid="fig11">Appendix 1—figure 5</xref> shows the occurrence drug addiction worsens treatment outcomes with 5% vs 31% eradicated tumours at a daily arresting effect of 0.25% (<italic>σ</italic> = 1.0%) for presence vs absence of drug addiction, respectively. Moreover, metronomic therapy results in a better outcome than a constantly administrated chemotherapy. For example, the former adds 6.6 additional years to the median detection time at <italic>σ</italic> = 1.0%, compared to the constant treatment with drug addiction, but loses 11.1 years, compared to the previous case of a constant treatment without drug addiction.<fig id="fig11" position="float"><object-id pub-id-type="doi">10.7554/eLife.06266.029</object-id><label>Appendix 1—figure 5.</label><caption><title>Comparing the case shown in blue in <xref ref-type="fig" rid="fig2">Figure 2</xref> with the case where resistant cells may become addicted to the drug.</title><p>The latter is illustrated by two treatment regimes: metronomic strategy (yellow) and constantly administrated drug (green). The plot shows the median and 90% confidence intervals (shaded areas) of detection times. The inset presents the fraction of cases when the tumour goes extinct after the initial lesion of 10<sup>6</sup> cells. Parameters as in <xref ref-type="table" rid="tbl1">Table 1</xref>.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.06266.029">http://dx.doi.org/10.7554/eLife.06266.029</ext-link></p></caption><graphic xlink:href="elife-06266-app1-fig5-v2.tif"/></fig></p></sec></boxed-text></app></app-group></back><sub-article article-type="article-commentary" id="SA1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.06266.030</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Bergstrom</surname><given-names>Carl T</given-names></name><role>Reviewing editor</role><aff><institution>University of Washington</institution>, <country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>eLife posts the editorial decision letter and author response on a selection of the published articles (subject to the approval of the authors). An edited version of the letter sent to the authors after peer review is shown, indicating the substantive concerns or comments; minor concerns are not usually shown. Reviewers have the opportunity to discuss the decision before the letter is sent (see <ext-link ext-link-type="uri" xlink:href="http://elifesciences.org/review-process">review process</ext-link>). Similarly, the author response typically shows only responses to the major concerns raised by the reviewers.</p></boxed-text><p>Thank you for sending your work entitled “Dynamics of preventive and reactive cancer control using low-impact measures” for consideration at <italic>eLife</italic>. Your article has been favorably evaluated by Diethard Tautz (Senior editor) and three reviewers, one of whom, Carl Bergstrom, is a member of our Board of Reviewing Editors.</p><p>The Reviewing editor and the other reviewers discussed their comments before we reached this decision, and the Reviewing editor has assembled the following comments to help you prepare a revised submission.</p><p>All three reviewers found this to be an interesting and timely paper that addresses a very important question. The work is well-conceived, attentive to detail, and well-interpreted. Nonetheless the reviewers raised a number of points which they felt should be addressed.</p><p>1) The authors use specific parameter values for their investigations. These parameters are presented in <xref ref-type="table" rid="tbl1">Table 1</xref>, and instead of giving biologically applicable ranges, the authors use particular values. In my opinion, it is important to investigate the range and not just a set of values. The paper would benefit greatly from some degree of sensitivity analysis to explain how results change as parameters change. For example, it is assumed that mutations are acquired with the rate 3.4x10^(<sup>-5</sup>). In reality, this parameter can vary over a very large range. It could be as low as 10^(<sup>-7</sup>) and as high as 10^(<sup>-2</sup>) in the presence of genomic instability. This is a change over five orders of magnitude, and can affect the results in a significant way. This should be addressed and discussed.</p><p>2) The authors assume that resistance presents a cost. At the same time, it has been suggested in the literature that some resistant mutations can actually be advantageous (e.g. in chronic lymphocytic leukemia). How will this alter the results?</p><p>3) It would be useful to discuss how the model applies or could be modified to apply to different types of therapies. Traditional therapies, more modern targeted therapies, and various sorts of combination treatments have very different properties. Often the source of resistance is not known. It is sometimes associated with specific mutations, and sometimes it has a different origin. The authors should explain how their model can be used in these different circumstances, and what modifications in the model correspond to different cases. Here we are looking less for additional modeling than for guidance on how the model could be adapted in future work.</p><p>4) Similarly, different cancers have different properties (solid tumors vs. leukemias, for example). It would be useful to discuss how future studies could extend the model to explicitly model different cancer types.</p><p>5) In the Abstract and throughout the paper, please clearly specify whether this paper is intended to address the implications of preventive/therapeutic interventions on the fate of a single aberrant clone, or on the fate of an individual patient. This distinction is important because cancer at almost any site in the body occurs in the context of additional subclinical aberrations in the population of cells. That is, most cancers arise in organs that are predisposed to cancer due to an interplay of inherited and exogenous influences (i.e., gene x environment interactions). Thus the process can be manifest not only in a single aberrant clone in one organ, but many concomitant clones within or across organs (e.g., long-term tobacco exposure places one at risk for myriad cancers in various organs) leading to synchronous and metachronous precancers and cancers.</p><p>6) The manuscript continually refers to “residual cells,” but the goal of most cancer-related surgeries is complete tumor removal. Complete resection is the foundation of cancer care wherever feasible. So it appears that this paper really relates to the fraction of cancer cases with residual or metastatic cancer. If so, that should be clarified in the title and background of the work (e.g. Dynamics of preventive and therapeutic interventions in patients with residual/metastatic cancer using low-impact measures).</p></body></sub-article><sub-article article-type="reply" id="SA2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.06266.031</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><p><italic>1) The authors use specific parameter values for their investigations. These parameters are presented in</italic> <xref ref-type="table" rid="tbl1"><italic>Table 1</italic></xref><italic>, and instead of giving biologically applicable ranges, the authors use particular values. In my opinion, it is important to investigate the range and not just a set of values. The paper would benefit greatly from some degree of sensitivity analysis to explain how results change as parameters change. For example, it is assumed that mutations are acquired with the rate 3.4x10^(</italic><sup><italic>-5</italic></sup><italic>). In reality, this parameter can vary over a very large range. It could be as low as 10^(</italic><sup><italic>-7</italic></sup><italic>) and as high as 10^(</italic><sup><italic>-2</italic></sup><italic>) in the presence of genomic instability. This is a change over five orders of magnitude, and can affect the results in a significant way. This should be addressed and discussed</italic>.</p><p>We used a canonical set of parameters, many based on biologically grounded estimates. We did in fact conduct sensitivity analyses for several of the most important parameters (e.g., <xref ref-type="fig" rid="fig2">Figure 2</xref> and its supplements). In reply to the reviewer’s request, we have now added an additional column to <xref ref-type="table" rid="tbl1">Table 1</xref>, indicating plausible ranges for parameter values, based on the literature. In addition, we conducted further sensitively analyses by varying mutation rates, finding that tumors exhibit more or less deterministic growth depending on the relation between the initial number of cells and additional driver mutation rate. This is analogous to the phenomenon shown in <xref ref-type="fig" rid="fig2s1">Figure 2–figure supplement 1D</xref>, whereby the higher the mutation rate, the less apparent are stochastic effects. The corresponding analysis is presented in Section B of <xref ref-type="app" rid="app1">Appendix 1</xref> (see also <xref ref-type="fig" rid="fig5">Figure 5</xref>). This is referenced by a paragraph in the Results, in the Preventive measures section.</p><p><italic>2) The authors assume that resistance presents a cost. At the same time, it has been suggested in the literature that some resistant mutations can actually be advantageous (e.g. in chronic lymphocytic leukemia). How will this alter the results</italic>?</p><p>This is a good point, and we agree that no cost, or more extreme situations such as drug addiction in resistant cell-lines (e.g., in certain melanomas (Das Thakur et al., 2014) or in leukemias (Michor et al., 2005), is important to consider for tumor management. Establishing optimized schedules in such situations is an intriguing problem that we plan to study in more detail in the future. In reply to the reviewers’ comment, we considered how drug addiction might alter our results. See Section C of <xref ref-type="app" rid="app1">Appendix 1</xref>. The corresponding paragraph in the main text is added to the end of the Results, Preventive measures section,. We also added two references (Das Thakur et al., 2014 and Fischer, Vásquez-García and Mustonen, 2015).</p><p><italic>3) It would be useful to discuss how the model applies or could be modified to apply to different types of therapies. Traditional therapies, more modern targeted therapies, and various sorts of combination treatments have very different properties. Often the source of resistance is not known. It is sometimes associated with specific mutations, and sometimes it has a different origin. The authors should explain how their model can be used in these different circumstances, and what modifications in the model correspond to different cases. Here we are looking less for additional modeling than for guidance on how the model could be adapted in future work</italic>.</p><p>Our current discussion does discuss cytotoxic vs. cytostatic effects (please see the subsection headed “Preventive interventions”). Although we agree that discussing model extensions to other types of therapy would be useful, it is unclear without actually modifying the model how these would alter the results, and as such we simply mention the importance of future study to consider these alternatives (in our Conclusion, we state: “Moreover, future studies should also investigate alternatives to the traditional post-diagnostic therapeutic scenarios considered here [e.g., molecularly targeted therapies (Yap, 2015)]”). We do however think it is important to stress the mutational basis for resistance, and as such have added text in the Discussion.</p><p><italic>4) Similarly, different cancers have different properties (solid tumors vs. leukemias, for example). It would be useful to discuss how future studies could extend the model to explicitly model different cancer types</italic>.</p><p>The second paragraph of the Conclusions now provides a series of possible modifications that can be made to our model to consider different cancer types and levels of resolution. Necessary references were also added.</p><p><italic>5) In the Abstract and throughout the paper, please clearly specify whether this paper is intended to address the implications of preventive/therapeutic interventions on the fate of a single aberrant clone, or on the fate of an individual patient. This distinction is important because cancer at almost any site in the body occurs in the context of additional subclinical aberrations in the population of cells. That is, most cancers arise in organs that are predisposed to cancer due to an interplay of inherited and exogenous influences (i.e., gene x environment interactions). Thus the process can be manifest not only in a single aberrant clone in one organ, but many concomitant clones within or across organs (e.g., long-term tobacco exposure places one at risk for myriad cancers in various organs) leading to synchronous and metachronous precancers and cancers</italic>.</p><p><ext-link ext-link-type="uri" xlink:href="http://tiny.cc/AkhmHoch15SVideos45">http://tiny.cc/AkhmHoch15SVideos45</ext-link>We now clarify that we are examining the simple situation of the fate of an individual patient confronted with single cancer. We have added text to the Abstract and Introduction clarifying this, and at the end of the Discussion stressed that future models should consider multiple independent or correlated events (same or different organs).</p><p><italic>6) The manuscript continually refers to</italic> “<italic>residual cells,</italic>” <italic>but the goal of most cancer-related surgeries is complete tumor removal. Complete resection is the foundation of cancer care wherever feasible. So it appears that this paper really relates to the fraction of cancer cases with residual or metastatic cancer. If so, that should be clarified in the title and background of the work (e.g. Dynamics of preventive and therapeutic interventions in patients with residual/metastatic cancer using low-impact measures)</italic>.</p><p>Prevention in our model acts on cancers before they are detected. What we now call “post-diagnostic interventions” (“reactive measures” in the original manuscript) involve resection followed by treatment. We assume that either resection itself is not perfect, and/or neighboring micro-metastases exist, and/or distant metastases are present, but undetected or non-removable. We show how the population number and (epi)genetic composition (in terms of drivers and resistance) of residual cells can have a major impact on both preventive (but initially failed) and post-diagnostic interventions (<xref ref-type="fig" rid="fig6">Figure 6A, C, E</xref> vs. <xref ref-type="fig" rid="fig6">Figure 6B, D, F</xref>). We now clarify this in the manuscript (please see the Introduction and the subsections entitled “Post-diagnostic interventions” and “Prevention vs. post-diagnostic intervention”).</p></body></sub-article></article>